Thienopyrrole Compounds

Abstract

The present disclosure relates generally to certain compounds, pharmaceutical compositions containing such compounds, and methods of making and using such compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of autoimmune diseases and / or inflammatory conditions, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 242,969, filed September 10, 2021, the entire contents of which are incorporated herein for all purposes. The present disclosure generally relates to thienopyrrole compounds, pharmaceutical compositions containing such compounds, and methods of making and using such compounds and pharmaceutical compositions. In some embodiments, the novel thienopyrrole compounds provided herein can be used to treat certain diseases and disorders, including, but not limited to, inflammatory conditions, systemic lupus erythematosus, cutaneous lupus erythematosus, or lupus nephritis. [Background technology]

[0002] Toll-like receptors (TLRs) are a family of transmembrane immune receptors that sense pathogens, trigger innate immune responses, and stimulate adaptive immunity. TLR7 / 8 / 9 are endosome-localized TLRs that respond to single-stranded RNA (TLR7 / 8) or unmethylated DNA containing cytosine-phosphate-guanine (CpG) motifs (TLR9). Activation of TLR7 / 8 / 9 leads to inflammatory responses, including the production of type I interferons and proinflammatory cytokines, B cell activation and antibody production, and neutrophil NETosis. Abnormal activation of TLR7 / 8 / 9 contributes to elevated type I interferon responses, increased proinflammatory cytokines, and sustained autoantibody production, which can stimulate the chronic progression of various autoimmune diseases and inflammatory conditions, resulting in widespread inflammation and tissue damage. (Kawai et al., 2010, Nat Immunol 11, 373; Joosten et al., 2016, Nat Rev Rheomatol 12, 344; Crow et al., 2019, Lupus Sci Med 6, e000336; Garcia-Romo et al., 2011, Sci Transl Med 3, 73ra20; Kono et al., 2009, PNAS 106, 12061; Koh et al., 2013, J Immunol 190, 4982). Thus, there is a need for compounds that are potent TLR7 and / or TLR8 and / or TLR9 antagonists that are stable and exhibit effective pharmacokinetic and / or pharmacodynamic profiles. [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] Kawai et al.,2010,Nat Immunol 11,373 [Non-patent document 2] Joosten et al.,2016,Nat Rev Rheomatol 12,344 [Non-patent document 3] Crow et al.,2019,Lupus Sci Med 6,e000336 [Non-patent document 4] Garcia-Romo et al.,2011,Sci Transl Med 3,73ra20 [Non-patent document 5] Kono et al.,2009,PNAS 106,12061 [Non-patent document 6] Koh et al.,2013,J Immunol 190,4982 Summary of the Invention [Means for solving the problem]

[0004] In one embodiment, a compound of formula I: [ka] or a pharmaceutically acceptable salt thereof, [In the formula, R 1 is an 8- to 15-membered fused tricyclic heterocyclyl or an 8- to 15-membered fused tricyclic heteroaryl, and the 8- to 15-membered fused tricyclic heterocyclyl and the 8- to 15-membered fused tricyclic heteroaryl each independently have 1 to 4 R a optionally substituted with a group, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; C 1~6 the alkoxy is optionally substituted with 1 to 3 halogen groups; R 3 is H, halogen, -CN, C 1~6 Alkyl and C 3~7 is a monocyclic cycloalkyl; C 1~6 Alkyl and C 3~7 Monocyclic cycloalkyls are each independently selected from -OH, halogen, -CN, and C1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups; Z is C 1~6 Alkyl, -C(O)R 13 -C(O)NR 6 R 7 , C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is one to four R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 The bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from the group consisting of 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, R 6 is C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C5~10 The bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 13 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, the 8- to 10-membered fused bicyclic heteroaryl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 7 But H, C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl or 4- to 6-membered monocyclic heterocyclyl, 1~6 Alkyl, C 3~7 The monocyclic cycloalkyl and the 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently halogen, -C(O)R 9 , -NR 10 R 10 , C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, -OR 5 , -C(O)N(R 5 )(R5 ), -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 ,-N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)N(R 5 )(R 5 ), -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O-, C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 The bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R 9 But independently, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R 5 and R 10 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R 5a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R a are independently oxo, imino, halogen, -NO2, -N3, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 3 R c and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R d and optionally substituted with a group, Each R b are independently oxo, imino, halogen, -NO2, -N3, -CN, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R d and optionally substituted with a group, Each R c are independently halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R d are independently oxo, halogen, -CN, C 1-6 Alkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a , -S(O)(NH)R 12 , -S(O)2R 12a , - S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, C 1~6 Alkyl is -OH, halogen, -CN, and C 1~3 optionally substituted with 1 to 3 groups independently selected from alkoxy; Each R 11 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R c and optionally substituted with a group, Each R11a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R c and optionally substituted with a group, Each R 12 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; Each R 12a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has from 1 to 4 ring heteroatoms independently selected from N, O, and S; Provided herein are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein each 8- to 15-membered fused tricyclic heterocyclyl and 8- to 15-membered fused tricyclic heteroaryl independently has 1-7 ring heteroatoms independently selected from N, O, and S.

[0005] In one embodiment, provided herein is a pharmaceutical composition comprising a compound provided herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

[0006] In one embodiment, provided herein is a method of inhibiting the activity of toll-like receptors 7 and / or 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0007] In one embodiment, provided herein is a method of inhibiting the activity of toll-like receptor 7 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0008] In one embodiment, provided herein is a method for inhibiting the activity of toll-like receptor 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0009] In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 7 and / or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0010] In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0011] In one embodiment, provided herein is a method of treating a disease or disorder associated with elevated toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0012] In one embodiment, provided herein is a method of treating an inflammatory condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0013] In one embodiment, provided herein is a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0014] In one embodiment, provided herein is a method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0015] In one embodiment, provided herein is a method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition provided herein.

[0016] In one embodiment, provided herein is a compound provided herein or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in therapy.

[0017] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting the activity of toll-like receptors 7 and / or 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0018] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treatment of toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0019] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of inhibiting the activity of toll-like receptor 8 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0020] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 and / or 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0021] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 7 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0022] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating a disease or disorder associated with elevated toll-like receptor 8 activity in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0023] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating an inflammatory condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0024] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating systemic lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition.

[0025] In one embodiment, provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein, for use in a method of treating cutaneous lupus erythematosus in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of the pharmaceutical composition. DETAILED DESCRIPTION OF THE INVENTION

[0026] I. Definition The following description is made with the understanding that the present disclosure should be considered as an example of claimed subject matter and is not intended to limit the scope of the appended claims to the particular embodiments illustrated. Headings used throughout this disclosure are for convenience only and should not be construed as limiting the scope of the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.

[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. It should be noted that as used in this specification and the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to a "compound" includes a plurality of such compounds, and a reference to an "assay" includes a reference to one or more assays and equivalents thereof known to those skilled in the art, etc.

[0028] As used in this disclosure, the following words, phrases, and symbols are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.

[0029] A dash ("-") that is not between two letters or symbols is used to indicate the point of attachment for a substituent. For example, -CONH2 is attached through a carbon atom. Dashes before or after chemical groups are for convenience; chemical groups may be designated with or without one or more dashes without losing their ordinary meaning. A wavy line drawn across a line in a structure indicates the point of attachment of the group. No directionality is indicated or implied by the order in which chemical groups are written or named, unless chemically or structurally required. A solid line extending from the center of a ring (including fused, bridged, or spirocyclic ring systems) indicates that the point of attachment of a substituent to that ring may be at any ring atom. For example, R in the following structure: aamay be attached to any of the five carbon ring atoms, or the hydrogen attached to the nitrogen ring atom may be attached to R aa may be replaced by: [ka] As another example, R in the following structure: aa So, [ka] R aa can be attached at any of the numbered positions shown below: [ka]

[0030] A solid line projecting from the center of a ring (including fused, bridged, or spirocyclic ring systems) indicates that the point of attachment of the ring system to the remainder of the compound can be at any ring atom of the fused, bridged, or spirocyclic ring system. For example, in the structure: [ka] The monocyclic heterocyclyl can be attached to the remainder of the compound at any of the numbered positions shown below: [ka] As another example, in the following fused bicyclic heterocyclic structure: [ka] The fused bicyclic heterocyclyl can be attached to the remainder of the compound at any of the eight numbered positions shown below: [ka]

[0031] "C u~vThe prefix "" indicates that the following group has carbon atoms u through v. For example, "C 1~6 "Alkyl group" indicates that the alkyl group has 1 to 6 carbon atoms. Similarly, the term "xy-membered" ring, where x and y are numerical ranges (e.g., "3-12-membered heterocyclyl"), refers to a ring having x to y (i.e., 3 to 12) atoms, up to 80% of which may be heteroatoms such as N, O, S, P, etc., and the remaining atoms are carbon.

[0032] Also, certain commonly used alternative chemical names may or may not be used. For example, divalent groups such as divalent "alkyl" groups, divalent "aryl" groups, etc. may also be referred to as "alkylene" or "alkylenyl" groups, or alkylyl groups, "arylene" or "arylenyl" groups, or aryl groups, respectively.

[0033] "Compounds disclosed herein" or "compounds of the disclosure" or "compounds provided herein" or "compounds described herein" refer to compounds of Formula I. Also included are the specific compounds of Examples 1-68.

[0034] Reference herein to "about" a value or parameter includes (and describes) embodiments related to the value or parameter itself. In certain embodiments, the term "about" includes the stated amount ±10%. In other embodiments, the term "about" includes the stated amount ±5%. In certain other embodiments, the term "about" includes the stated amount ±1%. Additionally, the term "about X" includes the description of "X."

[0035] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C 1~20 alkyl), having 1 to 12 carbon atoms (i.e., C 1~12 alkyl), having 1 to 8 carbon atoms (i.e., C 1~8 alkyl), having 1 to 6 carbon atoms (i.e., C 1~6alkyl), having 1 to 4 carbon atoms (i.e., C 1~4 alkyl), having 1 to 3 carbon atoms (i.e., C 1~3 alkyl), or having 1 to 2 carbon atoms (i.e., C 1~2 alkyl). Examples of alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl group having a specific number of carbon atoms is designated by a chemical name or identified by a molecular formula, all positional isomers having that number of carbon atoms can be included; thus, for example, "butyl" includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3), and "propyl" includes n-propyl (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).

[0036] "Alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond and having 2 to 20 carbon atoms (i.e., C 2~20 alkenyl), having 2 to 8 carbon atoms (i.e., C 2~8 alkenyl), having 2 to 6 carbon atoms (i.e., C 2~6 alkenyl), or having 2 to 4 carbon atoms (i.e., C 2~4 Alkenyl refers to an aliphatic group. Examples of alkenyl groups include ethenyl, propenyl, and butadienyl (including 1,2-butadienyl and 1,3-butadienyl).

[0037] "Alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond and having 2 to 20 carbon atoms (i.e., C 2~20 alkynyl), having 2 to 8 carbon atoms (i.e., C 2~8 alkynyl), having 2 to 6 carbon atoms (i.e., C 2~6alkynyl), or having 2 to 4 carbon atoms (i.e., C 2~4 alkynyl), an aliphatic group. The term "alkynyl" also includes alkynyl groups having one triple bond and one double bond.

[0038] "Alkylene" refers to a divalent unbranched saturated hydrocarbon chain. As used herein, alkylene has 1 to 20 carbon atoms (i.e., C 1~20 alkylene), having 1 to 12 carbon atoms (i.e., C 1~12 alkylene), having 1 to 8 carbon atoms (i.e., C 1~8 alkylene), having 1 to 6 carbon atoms (i.e., C 1~6 alkylene), having 1 to 4 carbon atoms (i.e., C 1~4 alkylene), having 1 to 3 carbon atoms (i.e., C 1~3 alkylene), or having 1 to 2 carbon atoms (i.e., C 1~2 alkylene). Examples of alkylene groups include methylene, ethylene, propylene, butylene, pentylene, and hexylene. In some embodiments, alkylene is optionally substituted with an alkyl group. Substituted alkylene groups include -CH(CH3)CH2-, -CH2CH(CH3)-, -CH2CH(CH2CH3)-, -CH2C(CH3)2-, -C(CH3)2CH2-, -CH(CH3)CH(CH3)-, -CH2C(CH2CH3)(CH3)-, and -CH2C(CH2CH3)2.

[0039] "Alkoxy" refers to an "alkyl-O-" group. Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. "Haloalkoxy" refers to an alkoxy group as defined above in which one or more hydrogen atoms have been replaced by halogen.

[0040] "Acyl" refers to the group -C(=O)R, where R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl, each of which can be optionally substituted as defined herein. Examples of acyl include formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.

[0041] "Amide" is -C(=O)NR y R z "C-amido" refers to the group, and -NR y C(=O)R z "N-amide group" refers to both the N-amide group and the N-amide group. y and R z is independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, heteroaryl, cycloalkyl, or heterocyclyl, each of which can be optionally substituted.

[0042] "Amino" is -NR y R z refers to a group, wherein R y and R z is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl, each of which can be optionally substituted.

[0043] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic), including fused systems. As used herein, aryl refers to a group having 6 to 20 ring carbon atoms (i.e., C 6~20 aryl), having 6 to 12 carbon ring atoms (i.e., C 6~12 aryl), or having 6 to 10 carbon ring atoms (i.e., C 6~10Aryl). Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthryl. However, aryl does not encompass or overlap in any way with heteroaryl, as defined below. When one or more aryl groups are fused to a heteroaryl ring, the resulting ring system is heteroaryl.

[0044] "Cyano" or "carbonitrile" refers to the group --CN.

[0045] "Cycloalkyl" refers to saturated or partially saturated cyclic alkyl groups having single or multiple rings, including fused, bridged, and spiro ring systems. The term "cycloalkyl" includes cycloalkenyl groups (i.e., cyclic groups having at least one double bond). As used herein, cycloalkyl refers to groups having 3 to 20 ring carbon atoms (i.e., C 3~20 cycloalkyl), having 3 to 12 ring carbon atoms (i.e., C 3~12 cycloalkyl), having 3 to 10 ring carbon atoms (i.e., C 3~10 cycloalkyl), having 3 to 8 ring carbon atoms (i.e., C 3~8 cycloalkyl), or having 3 to 6 ring carbon atoms (i.e., C 3~6 Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0046] "Cycloalkoxy" refers to the group "cycloalkyl-O-". Examples of cycloalkoxy groups include, but are not limited to, the following: [ka]

[0047] "Bridged" refers to a ring fusion in which different atoms on the ring are joined by a divalent substituent such as an alkylenyl group, an alkylenyl group containing one or two heteroatoms, or a single heteroatom. Quinuclidinyl and admantanyl are examples of bridged ring systems.

[0048] The term "fused" refers to rings that are joined to adjacent rings.

[0049] "Spiro" refers to a ring substituent joined by two bonds at the same carbon atom. Examples of spiro groups include 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4-methylpiperidine, where cyclopentane and piperidine, respectively, are spiro substituents.

[0050] "Halogen" or "halo" includes fluoro, chloro, bromo, and iodo.

[0051] "Haloalkyl" refers to an unbranched or branched alkyl group, as defined above, in which one or more hydrogen atoms have been replaced by a halogen. For example, if a residue is substituted with two or more halogens, it can be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two ("di") or three ("tri") halo groups, which may, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl (-CHF2) and trifluoromethyl (-CF3).

[0052] "Heteroalkylene" refers to a divalent unbranched saturated hydrocarbon chain having 1, 2, or 3 heteroatoms selected from NH, O, or S. As used herein, heteroalkylene refers to a heterocyclic group having 1 to 20 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~20 heteroalkylene; 1 to 8 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C1~8 heteroalkylene; 1 to 6 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~6 heteroalkylene; 1 to 4 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~4 heteroalkylene; 1 to 3 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~3 heteroalkylene); or 1 to 2 carbon atoms and 1, 2, or 3 heteroatoms selected from NH, O, and S (i.e., C 1~3 Heteroalkylene groups include -CH2CHO-, -CH2SCH2-, -CH2CHOCH2-, -CH2NHCH2-, and -CH2NHCH2-. In some embodiments, heteroalkylene is optionally substituted with an alkyl group. Examples of substituted heteroalkylene groups include -CH(CH3)N(CH3)CH2-, -CHOCH(CH3)-, -CH2CH(CH2CH3)S-, -CH2NHC(CH3)2-, -C(CH3)2SCH2-, -CH(CH3)N(CH3)CH(CH3)O-, -CH2SC(CH2CH3)(CH3)-, and -CH2C(CH2CH3)2NH-.

[0053] "Heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl refers to a group having 1 to 20 carbon ring atoms (i.e., C 1~20 heteroaryl), 3 to 12 carbon ring atoms (i.e., C 3~12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C 3~8Heteroaryl) and contains 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Heteroaryl does not encompass and does not overlap with aryl, as defined above.

[0054] "Heterocyclyl" or "heterocyclic ring" or "heterocycle" refers to a non-aromatic cyclic alkyl group having one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, "heterocyclyl" or "heterocyclic ring" or "heterocycle" refers to a saturated or partially saturated ring unless otherwise specified. For example, in some embodiments, "heterocyclyl" or "heterocyclic ring" or "heterocycle" refers to a partially saturated ring when specified. The term "heterocyclyl" or "heterocyclic ring" or "heterocycle" includes heterocycloalkenyl groups (i.e., heterocyclyl groups having at least one double bond). Heterocyclyls may be monocyclic or polycyclic, and polycyclic rings may be fused, bridged, or spiro. As used herein, heterocyclyls have 2 to 20 carbon ring atoms (i.e., C 2~20 heterocyclyl), having 2 to 12 carbon ring atoms (i.e., C 2~12 heterocyclyl), having 2 to 10 carbon ring atoms (i.e., C 2~10 heterocyclyl), having 2 to 8 carbon ring atoms (i.e., C 2~8 heterocyclyl), having 3 to 12 carbon ring atoms (i.e., C 3~12 heterocyclyl), having 3 to 8 carbon ring atoms (i.e., C 3~8 heterocyclyl), or having 3 to 6 carbon ring atoms (i.e., C 3~6Heterocyclyl; having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen. Examples of heterocyclyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl. As used herein, the term "bridged heterocyclyl" refers to a 4- to 10-membered ring moiety connected at two non-adjacent atoms of a heterocyclyl having one or more (e.g., one or two) 4- to 10-membered ring moieties, each heteroatom being independently selected from nitrogen, oxygen, and sulfur. As used herein, "bridged heterocyclyl" includes bicyclic and tricyclic ring systems. As used herein, the term "spiroheterocyclyl" refers to a ring system in which a 3- to 10-membered heterocyclyl has one or more additional rings, wherein the one or more additional rings are 3- to 10-membered cycloalkyl or 3- to 10-membered heterocyclyl, and a single atom of the one or more additional rings is also an atom of the 3- to 10-membered heterocyclyl. Examples of spiroheterocyclyls include bicyclic and tricyclic ring systems such as 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. As used herein, the terms "heterocycle," "heterocyclyl," and "heterocyclic ring" are used interchangeably. In some embodiments, the heterocyclyl is substituted with an oxo group.

[0055] "Heterocyclooxy" refers to the group "-O(heterocyclyl)". Examples of heterocyclooxy groups include, but are not limited to, -O(pyrrolidinyl), -O(tetrahydrofuranyl), -O(piperidinyl), -O(morpholinyl), -O(oxetanyl), and -O(2-oxa-7-azaspiro[3.5]nonanyl).

[0056] "Hydroxy" or "hydroxyl" refers to the group --OH.

[0057] "Oxo" refers to the (=O) or (O) radical.

[0058] "Sulfonyl" is -S(O)R bb refers to a group, wherein R bb is alkyl, haloalkyl, heterocyclyl, cycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.

[0059] Whenever a group illustration terminates in a single bonded nitrogen atom, that group represents an -NH group unless otherwise indicated. Similarly, unless otherwise stated, hydrogen atoms are implied and considered to be present when needed to complete valence or provide stability, given the knowledge of those skilled in the art.

[0060] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes cases where the event or circumstance occurs and cases where the event or circumstance does not. Also, the term "optionally substituted" means that any one or more hydrogen atoms on a specified atom or group may or may not be replaced by a non-hydrogen moiety.

[0061] The term "substituted" means that any one or more hydrogen atoms on the specified atom or group are replaced with one or more substituents other than hydrogen, provided that the normal valence of the specified atom is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanato, thiol, thione, or combinations thereof. Polymers or similar amorphous structures resulting from defining the substituents with an infinite number of additional substituents (e.g., substituted aryls with substituted alkyls, which themselves are substituted with substituted aryl groups, which are further substituted with substituted heteroalkyl groups, etc.) are not intended to be included herein. Unless otherwise specified, the maximum number of consecutive substitutions in the compounds described herein is three. For example, consecutive substitution of a substituted aryl group with two other substituted aryl groups is limited to ((substituted aryl)substituted aryl)substituted aryl. Similarly, the above definition is not intended to include impermissible substitution patterns (e.g., methyl substituted with five fluorines or a heteroaryl group having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to those of ordinary skill in the art. When used to modify a chemical group, the term "substituted" can describe other chemical groups defined herein. For example, the term "substituted aryl" includes, but is not limited to, "alkylaryl." Unless otherwise specified, if a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.

[0062] In some embodiments, the substituted cycloalkyl, substituted heterocyclyl, substituted aryl, and / or substituted heteroaryl includes a cycloalkyl, heterocyclyl, aryl, and / or heteroaryl having a substituent on a ring atom, where the cycloalkyl, heterocyclyl, aryl, and / or heteroaryl is attached to the remainder of the compound. For example, in the moiety below, the cyclopropyl is substituted with a methyl group: [ka]

[0063] The compounds of the embodiments disclosed herein, or pharmaceutically acceptable salts thereof, may contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, with respect to absolute stereochemistry, as (R)- or (S)-, or for amino acids, as (D)- or (L)-. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+)- and (−), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors, or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC). When compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, these compounds are intended to include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. When compounds are represented in their chiral form, it is understood that embodiments include, but are not limited to, the specific diastereomerically or enantiomerically enriched forms. Where chirality is not specified, it is understood that embodiments are directed to either the specific diastereomerically or enantiomerically enriched forms, or racemic or scalemic mixtures of such compounds. As used herein, a "scalemic mixture" is a mixture of stereoisomers in a ratio other than 1:1.

[0064] "Stereoisomers" refer to compounds made up of the same atoms connected by the same bonds but with different, not interchangeable, three-dimensional structures. The present disclosure contemplates various stereoisomers and mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose molecules are non-superimposable mirror images of one another.

[0065] "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. A mixture of enantiomers in a ratio other than 1:1 is a "scalemic" mixture.

[0066] "Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.

[0067] "Tautomer" refers to a proton migration from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any compounds provided herein.

[0068] Some of the compounds provided herein exist as tautomeric isomers. Tautomers are in equilibrium with each other. For example, an amide-containing compound may exist in equilibrium with an imidic acid tautomer. Regardless of which tautomer is shown and the nature of the equilibrium between the tautomers, it is understood by those skilled in the art that the compounds include both the amide and imidic acid tautomers. Thus, amide-containing compounds are understood to include their imidic acid tautomers. Similarly, imidic acid-containing compounds are understood to include their amide tautomers.

[0069] A "solvate" is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds provided herein are also provided. Hydrates of the compounds provided herein are also provided.

[0070] Any formula or structure provided herein is also intended to represent unlabeled and isotopically labeled forms of the compound.Isotopically labeled compounds have the structure shown by the formula provided herein, except that one or more atoms are replaced by atoms having a selected atomic mass or mass number.Examples of isotopes that can be incorporated into compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as:2 H (deuterium, D), 3 H (tritium), 11 C. 13 C. 14 C. 15 N, 18 F, 31 P, 32 P, 35 S, 36 Cl and 125 I. Various isotopically labeled compounds of the present disclosure include, but are not limited to, 2 H, 3 H, 13 C and 14 Also provided herein are compounds into which a radioactive isotope, such as C, is incorporated. Such isotopically labeled compounds may be useful in detection or imaging techniques such as metabolism studies, reaction kinetic studies, positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radiation treatment of patients.

[0071] The present disclosure also includes compounds of Formula I in which 1 to n hydrogens bonded to carbon atoms have been replaced by deuterium, where n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are therefore useful for extending the half-life of any compound of Formula I when administered to a mammal, particularly a human. See, e.g., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example, by employing starting materials in which one or more hydrogens have been replaced by deuterium.

[0072] Deuterium-labeled or deuterium-substituted therapeutic compounds of the present disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties related to absorption, distribution, metabolism, and excretion (ADME). Substitution with heavier isotopes, such as deuterium, may confer certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life, reduced dosage requirements, and / or improved therapeutic index. 18 F-labeled compounds can be useful in PET or SPECT studies.The isotopically labeled compounds of the present disclosure and their prodrugs can generally be prepared by replacing readily available isotopically labeled reagents with non-isotopically labeled reagents, and carrying out the procedures disclosed in the schemes or in the examples and preparations described below.In this context, it is understood that deuterium is considered to be a substituent in the compound of formula I.

[0073] The concentration of such heavier isotopes, specifically deuterium, can be defined by the isotopic enrichment factor. In the compounds of the present disclosure, any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise specified, when a position is specifically designated as "H" or "hydrogen," the position is understood to have that hydrogen at the natural abundance isotopic composition of hydrogen. Thus, in the compounds of the present disclosure, any atom specifically designated as deuterium (D) is meant to represent deuterium.

[0074] In many cases, the compounds of the present disclosure are capable of forming acid and / or base salts by virtue of the presence of amino and / or carboxyl groups or groups similar thereto.

[0075] The term "pharmaceutically acceptable salt" of a given compound refers to a salt that retains the biological effectiveness and properties of the given compound and is not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, such as alkylamines, dialkylamines, trialkylamines, substituted alkylamines, di(substituted alkyl)amines, tri(substituted alkyl)amines, alkenylamines, dialkenylamines, trialkenylamines, substituted alkenylamines, di(substituted alkenyl)amines, tri(substituted alkenyl)amines, mono-, di-, or tricycloalkylamines, mono-, di-, or triarylamines, or mixed amines. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(iso-propyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0076] Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc.

[0077] As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

[0078] "Treatment" or "treating" is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results can include one or more of the following: a) inhibiting the disease or condition (i.e., reducing one or more symptoms resulting from the disease or condition and / or attenuating the severity of the disease or condition), b) slowing or arresting the onset of one or more clinical symptoms associated with the disease or condition (i.e., stabilizing the disease or condition, preventing or slowing the worsening or progression of the disease or condition, and / or preventing or slowing the spread (i.e., metastasis) of the disease or condition), and / or c) palliating the disease, i.e., causing regression of clinical symptoms (i.e., improving the disease state, providing partial or complete remission of the disease or condition, enhancing the effect of another drug, slowing the progression of the disease, improving quality of life, and / or prolonging survival).

[0079] "Prevention" or "preventing" means any treatment of a disease or condition that results in the non-development of clinical symptoms of the disease or condition. In some embodiments, the compounds may be administered to subjects (including humans) who are at risk or have a family history of the disease or condition.

[0080] "Subject" refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful in human therapy and / or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human.

[0081] The term "therapeutically effective amount" or "effective amount" of a compound described herein, or a pharmaceutically acceptable salt, isomer, or mixture thereof, means an amount sufficient to effect treatment and provide a therapeutic benefit, such as amelioration of symptoms or slowing of disease progression, when administered to a subject. For example, a therapeutically effective amount can be an amount sufficient to ameliorate the symptoms of a disease or condition in response to inhibition of toll-like receptors 7, 8, and / or 9. A therapeutically effective amount may vary depending on the subject, the disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the mode of administration, and can be readily determined by one of ordinary skill in the art. II. Compounds

[0082] In one embodiment, a compound of formula I: [ka] or a pharmaceutically acceptable salt thereof, [In the formula, R 1 is an 8- to 15-membered fused tricyclic heterocyclyl or an 8- to 15-membered fused tricyclic heteroaryl, and the 8- to 15-membered fused tricyclic heterocyclyl and the 8- to 15-membered fused tricyclic heteroaryl each independently have 1 to 4 R a optionally substituted with a group, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; C 1~6 the alkoxy is optionally substituted with 1 to 3 halogen groups; R 3 is H, halogen, -CN, C1~6 Alkyl and C 3~7 is a monocyclic cycloalkyl; C 1~6 Alkyl and C 3~7 Monocyclic cycloalkyls are each independently selected from -OH, halogen, -CN, and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups; Z is C 1~6 Alkyl, -C(O)R 13 -C(O)NR 6 R 7 , C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl is one to four R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 The bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from the group consisting of 1 to 2 R 8 groups, each independently being 1 to 3 R a and optionally substituted with a group, R 6 is C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 The bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 13 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, the 8- to 10-membered fused bicyclic heteroaryl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a and optionally substituted with a group, R 7 But H, C 1~6 Alkyl, C 3~7 monocyclic cycloalkyl or 4- to 6-membered monocyclic heterocyclyl, 1~6 Alkyl, C 3~7 The monocyclic cycloalkyl and the 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R 8 are independently halogen, -C(O)R 9 , -NR 10 R 10 , C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, -OR 5 , -C(O)N(R 5 )(R 5 ), -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 ,-N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)N(R 5 )(R 5 ), -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ), or -N=S(R 5a )(R 5a )=O-, C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 The bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R 9 But independently, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R 5 and R 10 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R 5a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a and optionally substituted with a group, Each R a are independently oxo, imino, halogen, -NO2, -N3, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 3 R c and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R d and optionally substituted with a group, Each R b are independently oxo, imino, halogen, -NO2, -N3, -CN, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R d and optionally substituted with a group, Each R c are independently halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R d are independently oxo, halogen, -CN, C 1-6 Alkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a , -S(O)(NH)R 12 , -S(O)2R 12a , - S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, C 1~6 Alkyl is -OH, halogen, -CN, and C 1~3 optionally substituted with 1 to 3 groups independently selected from alkoxy; Each R 11 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R c and optionally substituted with a group, Each R11a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R c and optionally substituted with a group, Each R 12 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; Each R 12a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has from 1 to 4 ring heteroatoms independently selected from N, O, and S; Provided herein are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein each 8- to 15-membered fused tricyclic heterocyclyl and 8- to 15-membered fused tricyclic heteroaryl independently has 1-7 ring heteroatoms independently selected from N, O, and S.

[0083] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 7~10 a fused bicyclic cycloalkyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; C 7~10 The fused bicyclic cycloalkyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R 8groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0084] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is 1 to 4 R a 8-15 membered fused tricyclic heterocyclyl optionally substituted by a group; R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups; R 3 is H or C 1~6 is alkyl, C 1~6 Alkyl is -OH, halogen, -CN, and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups; Z is a 4- to 7-membered monocyclic heterocyclyl, phenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently 1 to 3 R a optionally substituted with a group, Each R 8 are independently -C(O)R 9 , C 1~6 Alkyl, 4- to 7-membered monocyclic heterocyclyl, or -S(O)R 5aand C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one to four R a and optionally substituted with a group, Each R 9 independently, C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl, C 3~7 The monocyclic cycloalkyl and the 4- to 7-membered monocyclic heterocyclyl each independently have 1 to 4 R a optionally substituted with a group, R 5a is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a and optionally substituted with a group, Each R a are independently oxo, imino, halogen, -NO2, -N3, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 3 R c and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R d and optionally substituted with a group, Each R b are independently oxo, imino, halogen, -NO2, -N3, -CN, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R d and optionally substituted with a group, Each R c are independently halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, Each R d are independently oxo, halogen, -CN, C 1-6 Alkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a , -S(O)(NH)R 12 , -S(O)2R 12a , - S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R12a )=O, Each R 11 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C v1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R c and optionally substituted with a group, Each R 11a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R c and optionally substituted with a group, Each R 12 However, independently, H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; Each R 12a But independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has from 1 to 4 ring heteroatoms independently selected from N, O, and S; Provided herein are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein each 8- to 15-membered fused tricyclic heterocyclyl and 8- to 15-membered fused tricyclic heteroaryl independently has 1-7 ring heteroatoms independently selected from N, O, and S.

[0085] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~6 Alkyl and C 3~7 an 8- to 15-membered fused tricyclic heterocyclyl optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl; R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 optionally substituted with 1 to 4 groups independently selected from alkoxy; R 3 is H or C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; Z is a 4- to 7-membered monocyclic heterocyclyl, phenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; Each R 8 are independently -C(O)R 9 , C 1~6 Alkyl, 4- to 7-membered monocyclic heterocyclyl, or -S(O)R 5a and C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , C 1~4 Alkoxy, and R 8a and optionally substituted with 1 to 3 groups independently selected from 4-7 membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; Each R 8a are independently 4- to 7-membered monocyclic heterocyclyl or 5- to 6-membered monocyclic heteroaryl, and the 4- to 7-membered monocyclic heterocyclyl and the 5- to 6-membered monocyclic heteroaryl are each independently —OH, halogen, C 1~4 Alkoxy and C 1~5optionally substituted with 1 to 3 groups independently selected from alkyl; Each R 9 independently, C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl, 3-7 The monocyclic cycloalkyl and the 4- to 7-membered monocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl and 4- to 7-membered monocyclic heterocyclyl; R 5a is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; Each R 11 are independently H or C 1~6 is alkyl, Each R 12 are independently H or C 1~4 is alkyl, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl independently has from 1 to 4 ring heteroatoms independently selected from N, O, and S; Provided herein are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein each 8- to 15-membered fused tricyclic heterocyclyl and 8- to 15-membered fused tricyclic heteroaryl independently has 1-7 ring heteroatoms independently selected from N, O, and S.

[0086] Unless otherwise specified, each 4-membered monocyclic heterocyclyl as used herein has one ring heteroatom selected from N, O, and S. Unless otherwise specified, each 5- to 7-membered monocyclic heterocyclyl as used herein has one to two ring heteroatoms independently selected from N, O, and S. Unless otherwise specified, each 6-membered bridged bicyclic heterocyclyl as used herein has one ring heteroatom selected from N, O, and S. Unless otherwise specified, each 7-membered bridged bicyclic heterocyclyl as used herein has one to two ring heteroatoms independently selected from N, O, and S. Unless otherwise specified, each 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl as used herein independently has 1 to 4 ring heteroatoms independently selected from N, O, and S.

[0087] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heterocyclyl, and the 8- to 15-membered fused tricyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heterocyclyl, and the 8- to 15-membered fused tricyclic heterocyclyl is aIn some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heterocyclyl, and the 8- to 15-membered fused tricyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~6 Alkyl, and C 3~7 Optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl.

[0088] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heterocyclyl, and the 8- to 15-membered fused tricyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heterocyclyl, and the 8- to 15-membered fused tricyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heterocyclyl, and the 8- to 15-membered fused tricyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~6 Alkyl, and C 3~7 and is substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl.

[0089] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heterocyclyl.

[0090] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1is an 8- to 15-membered fused tricyclic heteroaryl, and the 8- to 15-membered fused tricyclic heteroaryl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heteroaryl, and the 8- to 15-membered fused tricyclic heteroaryl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heteroaryl, and the 8- to 15-membered fused tricyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~6 Alkyl, and C 3~7 Optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl.

[0091] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heteroaryl, and the 8- to 15-membered fused tricyclic heteroaryl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heteroaryl, and the 8- to 15-membered fused tricyclic heteroaryl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 is an 8- to 15-membered fused tricyclic heteroaryl, and the 8- to 15-membered fused tricyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~6 Alkyl, and C 3~7 and is substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl.

[0092] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 teeth, [ka] Halogen, C 1~3 Alkyl and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy, wherein C 1~3 The alkyl is optionally substituted with 1 to 3 halogen groups.

[0093] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 teeth, [ka] is.

[0094] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 teeth, [ka] Each R 1a are independently H, -CN, and C 1~6 Alkyl, C 1~5 Alkoxy or C 3~7 is a monocyclic cycloalkyl, C 1~6 Alkyl and C 1~5 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0095] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 1a are independently H, —CN, —CHF 2 , —CF 3 , methyl, methoxy, or cyclopropyl.

[0096] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 1 teeth, [ka]

[0097] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 Optionally substituted with 1 to 3 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 4 halogen groups. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 Optionally substituted with 1 to 3 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy; 1~3 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 substituted with 1 to 4 groups independently selected from alkoxy; 1~6 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 substituted with 1 to 3 groups independently selected from alkoxy; 1~6The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 substituted with 1 to 3 groups independently selected from alkoxy; 1~3 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0098] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~6In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~6 alkyl, C 1~6 Alkyl is halogen and C 1~3 and substituted with 1 to 3 groups independently selected from alkoxy.

[0099] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy.

[0100] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~6In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkoxy. 2 is C 1~4 alkyl, C 1~4 Alkyl is halogen and C 1~3 and substituted with 1 to 3 groups independently selected from alkoxy.

[0101] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~4 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is ethyl or isopropyl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is methyl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 2 is isopropyl.

[0102] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 3 is H, halogen, -CN, C 1~6 Alkyl or C 3~7 It is a monocyclic cycloalkyl. C 1~6 Alkyl and C 3~7 Monocyclic cycloalkyls are each independently selected from -OH, halogen, -CN, and C 1~4optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0103] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is H or C 1~6 is alkyl, C 1~6 Alkyl is -OH, halogen, -CN, and C 1~4 optionally substituted with 1 to 3 groups independently selected from alkoxy; C 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups.

[0104] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is H or C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN and C 1~4 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 3 is H or C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is H or methyl.

[0105] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is H. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is halogen. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is -CN.

[0106] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is C3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl includes -OH, halogen, -CN and C 1~4 Optionally substituted with 1 to 3 groups independently selected from alkoxy; 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl includes -OH, halogen, -CN and C 1~4 substituted with 1 to 3 groups independently selected from alkoxy; 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is C 3~7 It is a monocyclic cycloalkyl.

[0107] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, and C 1~4 Optionally substituted with 1 to 3 groups independently selected from alkoxy; 1~4 The alkoxy is optionally substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, and C 1~4 Optionally substituted with 1 to 3 groups independently selected from alkoxy; 1~4 The alkoxy is substituted with 1 to 3 halogen groups.

[0108] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is C 1~6 alkyl, C1~6 Alkyl is -OH, halogen, -CN, and C 1~4 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkoxy. 3 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, and C 1~4 and substituted with 1 to 3 groups independently selected from alkoxy.

[0109] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 -OH, halogens, -CN and C 1~3 C optionally substituted with 1 to 3 groups independently selected from alkoxy 1~4 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is methyl substituted with 1 to 3 halogen groups. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is -CHF2.

[0110] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is C 1~4 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 3 is methyl.

[0111] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is C 1~6 Alkyl, -C(O)R 13 , -C(O)NR 6 R7 , C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 It is a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, phenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl. C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 The bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from the group consisting of 1 to 2 R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0112] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 7~10 a fused bicyclic cycloalkyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; C 7~10 The fused bicyclic cycloalkyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0113] In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, phenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently 1 to 3 R a is optionally substituted with a group.

[0114] In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, phenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R 8 groups, each independently selected from the group consisting of —OH, halogen, —CN, oxo, and —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0115] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 7~10 a fused bicyclic cycloalkyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; C 7~10The fused bicyclic cycloalkyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R 8 groups, each independently being 1 to 3 R a is optionally substituted with a group.

[0116] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is C 1~6 alkyl, C 1~6 Alkyl is one to four R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C 1~6 alkyl, C 1~6 Alkyl is one to three R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C 1~6 alkyl, C 1~6 Alkyl is one to four R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 1~6 alkyl, C 1~10 Alkyl is one to three R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 1~6 It is alkyl.

[0117] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 2 R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 2 R8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0118] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 2 R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 2 R 8 Substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0119] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 2 R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 2 R 8 Substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5and substituted with 1 to 3 groups independently selected from alkyl.

[0120] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 2 R 8 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl includes -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from C 3~7 It is a monocyclic cycloalkyl.

[0121] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, each of which is selected from the group consisting of 1 to 2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl, cyclobutanyl, cyclopentanyl, or cyclohexanyl, each of which is optionally substituted with 1 to 2 R 8 Substituted with -OH, halogen, -CN, oxo, -NR 11 R11 , C 1~4 Alkoxy and C 1~5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, each of which is optionally substituted with 1 to 3 groups independently selected from R 8 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is cyclobutanyl, cyclopentanyl, or cyclohexanyl, which are each independently substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0122] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl has one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl has one to two R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl has one to two R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl has one to two R8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to three R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 7~10 It is a fused bicyclic cycloalkyl.

[0123] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has one to two R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has one to two R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is substituted with a C group. 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 3 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with a C group. 5~10 It is a bridged bicyclic cycloalkyl.

[0124] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is substituted with one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl.

[0125] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 optionally substituted with a group and 1 to 3 R aIn some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0126] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0127] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5and substituted with 1 to 3 groups independently selected from alkyl.

[0128] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heterocyclyl, wherein the 5- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl.

[0129] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is selected from the group consisting of 1 to 2 R 8 optionally substituted with 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0130] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is selected from the group consisting of 1 to 2 R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is optionally substituted with one to two R8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0131] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is selected from the group consisting of 1 to 2 R 8 substituted with 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0132] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is selected from the group consisting of 1 to 2 R 8 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is phenyl, and the phenyl is substituted with 1 to 3 R groups. a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is phenyl, and phenyl is optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl.

[0133] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is selected from the group consisting of 1-2 R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is optionally substituted with one to two R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is optionally substituted with one to two R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is substituted with one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is substituted with 1-3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl.

[0134] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is selected from the group consisting of 1-2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is selected from the group consisting of 1-2 R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is selected from the group consisting of 1-2 R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0135] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0136] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0137] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0138] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from one to two R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl, wherein the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl.

[0139] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0140] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 group and 1 to 3 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0141] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0142] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl, wherein the 6- to 10-membered bridged bicyclic heterocyclyl is substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0143] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from 1 to 2 R 8 optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0144] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from 1 to 2 R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0145] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from 1 to 2 R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0146] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is selected from 1 to 2 R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is substituted with 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heteroaryl, wherein the 8- to 10-membered fused bicyclic heteroaryl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl, 8 to 10 membered fused bicyclic heteroaryl.

[0147] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8optionally substituted with a group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is optionally substituted with one to two R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0148] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is optionally substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0149] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 group and 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl, wherein the 7- to 10-membered spirocyclic heterocyclyl is substituted with one to two R 8 and substituted with -OH, halogen, -CN, oxo, -NR11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0150] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of 1 to 2 R 8 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7-10 membered spirocyclic heterocyclyl, wherein the 7-10 membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is optionally substituted with 1 to 3 groups independently selected from alkyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl.

[0151] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl, wherein the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of one R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0152] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 4- to 7-membered monocyclic heterocyclyl. 4- to 7-membered monocyclic heterocyclyl is one R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5optionally substituted with 1 to 3 groups independently selected from alkyl; A 4- to 7-membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0153] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is 5-6 membered monocyclic heterocyclyl. 5-6-membered monocyclic heterocyclyl is one R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 2 groups independently selected from alkyl; A 5-6 membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0154] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is piperidinyl, and the piperidinyl is 8 is optionally substituted with a group.

[0155] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is phenyl or a 5- to 6-membered monocyclic heteroaryl, each of which is selected from one R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0156] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 and phenyl optionally substituted with a group.

[0157] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 5-6 membered monocyclic heteroaryl, and the 5-6 membered monocyclic heteroaryl is selected from the group consisting of one R 8 The ring heteroatoms are optionally substituted with N groups and have 1, 2 or 3 ring heteroatoms which are N.

[0158] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is pyridinyl or [ka] Each of these optionally contains one R 8 is substituted with a group.

[0159] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 and optionally substituted with —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and 8-10 membered fused bicyclic heterocyclyl optionally substituted with 1-2 groups independently selected from alkyl.

[0160] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is an 8- to 10-membered fused bicyclic heterocyclyl. 8- to 10-membered fused bicyclic heterocyclyl is one R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 2 groups independently selected from alkyl; The 8-10 membered fused bicyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0161] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is [ka] Each of these optionally contains one R 8 is substituted with a group.

[0162] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 Optionally substituted with groups such as -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and 6-10 membered bridged bicyclic heterocyclyl optionally substituted with 1 to 2 groups independently selected from alkyl.

[0163] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is a 6- to 10-membered bridged bicyclic heterocyclyl. 6- to 10-membered bridged bicyclic heterocyclyl is 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 2 groups independently selected from alkyl; A 6- to 10-membered bridged bicyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0164] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is [ka] Each of these optionally contains one R 8 is substituted with a group.

[0165] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is selected from one R 8 Optionally substituted with groups such as -OH, halogen, -CN, oxo, -NR 11 R11 , C 1~4 Alkoxy, and C 1~5 and 7-10 membered spirocyclic heterocyclyl optionally substituted with 1-2 groups independently selected from alkyl.

[0166] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is a 7- to 10-membered spirocyclic heterocyclyl; 7-10 membered spirocyclic heterocyclyl is substituted with 1-2 R 8 and optionally substituted with -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with one group independently selected from alkyl; A 7-10 membered spirocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0167] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is [ka] This can optionally be one R 8 is substituted with a group.

[0168] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is [ka] This can optionally be one R 8 is substituted with a group.

[0169] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one R 8 Z substituted with a group is [ka]

[0170] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 8 are independently halogen, -C(O)R 9 , -NR 10 R 10 , C 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 6-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, 7-10 membered spirocyclic heterocyclyl, -OR 5 , -C(O)N(R 5 )(R 5 ), -N(R 5 )2(R 5 ) + , -N(R 5 )C(O)R 5 , -N(R 5 )C(O)OR 5 , -N(R 5 )C(O)N(R 5 )(R 5 ), -N(R 5 )S(O)2(R 5a ), -NR 5 S(O)2N(R 5 )(R 5 ), -NR 5 S(O)2O(R 5a ), -OC(O)N(R 5 )(R 5 ), -S(O)R 5a , -S(O)(NH)R 5 , -S(O)2R 5a , -S(O)2N(R 5 )(R 5 ) or -N=S(R 5a )(R 5a )=O, C 1~6 Alkyl is 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C7~10 Fused Bicyclic Cycloalkyl, C 5~10 The bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R a is optionally substituted with a group.

[0171] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 8 are independently -C(O)R 9 , C 1~6 Alkyl, 4- to 7-membered monocyclic heterocyclyl, or -S(O)R 5a and C 1~6 Alkyl is one to four R b and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one to four R a is optionally substituted with a group.

[0172] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 8 are independently -C(O)R 9 , C 1~6 Alkyl, 4- to 7-membered monocyclic heterocyclyl, or -S(O)R 5a and C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , C 1~4 Alkoxy, and R 8a and optionally substituted with 1 to 3 groups independently selected from 4- to 7-membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0173] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or both of R 8 Either one or both of the following is -OR 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups may be -C(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -N(R 5 )2(R 5 ) + In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups may be -N(R 5 )C(O)R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -N(R 5 )C(O)OR 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups may be -N(R 5 )C(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the following is -N(R 5 )S(O)2(R 5a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups may be -NR 5 S(O)2N(R 5 )(R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8One or both of the following is -NR 5 S(O)2O(R 5a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of -OC(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups may be -S(O)R 5a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are -S(O)(NH)R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of -S(O)N(R 5 )(R 5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of -N=S(R 5a )(R 5a )=O.

[0174] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~6 alkyl, C 1~6 Alkyl is one to four R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~6 alkyl, C 1~6 Alkyl has 1 to 3 R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11), C 1~4 Alkoxy, R 8a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~3 alkyl, C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), C 1~4 Alkoxy, and R 8a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~3 alkyl, C 1~3 Alkyl is oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), and R 8a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~6 alkyl, C 1~6 Alkyl is 1 to 4 R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~6 alkyl, C 1~6 Alkyl has 1 to 3 R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), C 1~4Alkoxy, and R 8a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~6 alkyl, C 1~6 Alkyl includes -OH, oxo, -NH, -N(CH), -C(O)NH, -C(O)N(CH), and R 8a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~6 alkyl, C 1~6 Alkyl is —OH, oxo, —N(CH3)2, —C(O)NH2, and R 8a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~3 alkyl, C 1~3 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), C 1~4 Alkoxy, and R 8a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~3 alkyl, C 1~3 Alkyl is oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), and R 8a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of1~3 It is alkyl.

[0175] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 1~6 alkyl, C 1~6 Alkyl includes -OH, oxo, -N(CH3)2, -C(O)NH2, -C(O)NHCH3, and R 8a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, oxo, -N(CH3)2, -C(O)NH2, -C(O)NHCH3, R 8a is substituted with 1 to 3 groups independently selected from

[0176] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 3~7 It is a monocyclic cycloalkyl.

[0177] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R aIn some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 7~10 It is a fused bicyclic cycloalkyl.

[0178] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of 5~10 It is a bridged bicyclic cycloalkyl.

[0179] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0180] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0181] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups is a 4- to 7-membered monocyclic heterocyclyl.

[0182] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is a 5- to 6-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is a 5- to 6-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0183] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is a 5- to 6-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is a 5- to 6-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0184] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups is a 5- to 6-membered monocyclic heterocyclyl.

[0185] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8is phenyl, and the phenyl is selected from 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is phenyl, and the phenyl is selected from 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of is phenyl.

[0186] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups is a 5- to 6-membered monocyclic heteroaryl.

[0187] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 or both of the 8- to 10-membered fused bicyclic heterocyclyl are 8- to 10-membered fused bicyclic heterocyclyls, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0188] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 or both of the 8- to 10-membered fused bicyclic heterocyclyl are 8- to 10-membered fused bicyclic heterocyclyls, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0189] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups is a fused 8- to 10-membered bicyclic heterocyclyl.

[0190] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl isa In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0191] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0192] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0193] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 7- to 8-membered bridged bicyclic heterocyclyl, and the 7- to 8-membered bridged bicyclic heterocyclyl isa In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 7- to 8-membered bridged bicyclic heterocyclyl, and the 7- to 8-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 7- to 8-membered bridged bicyclic heterocyclyl, and the 7- to 8-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0194] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 7- to 8-membered bridged bicyclic heterocyclyl, and the 7- to 8-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 7- to 8-membered bridged bicyclic heterocyclyl, and the 7- to 8-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 7- to 8-membered bridged bicyclic heterocyclyl, and the 7- to 8-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0195] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of is a 7-8 membered bridged bicyclic heterocyclyl.

[0196] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups is a 7- to 10-membered spirocyclic heterocyclyl.

[0197] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0198] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or both of R is a 7-10 membered spirocyclic heterocyclyl, which is optionally substituted with 1-3 groups independently selected from oxo and methyl. 8 One or both of the groups are 7-10 membered spirocyclic heterocyclyl, and the 7-10 membered spirocyclic heterocyclyl is substituted with 1-3 groups independently selected from oxo and methyl.

[0199] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of [ka] Each of these may be optionally substituted with one methyl group. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of [ka] Each of these is substituted with one methyl group.

[0200] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0201] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 4- to 7-membered monocyclic heterocyclyl; 4-7 membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; A 4- to 7-membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms independently selected from N and S.

[0202] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0203] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is piperidinyl or piperazinyl, each of which is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0204] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is piperidinyl or piperazinyl.

[0205] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)NR 11 R 11 , C 1~4 Alkoxy, and R 8a and optionally substituted with 1 to 3 groups independently selected from:

[0206] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is C 1~6 alkyl, C 1~6 Alkyl is -C(O)NR 11 R 11 and R 8a is substituted with 1 to 2 groups independently selected from

[0207] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 is C 1~4 alkyl, C 1~4 The alkyl is substituted with 1 to 2 groups independently selected from -C(O)NH2, a 4- to 7-membered monocyclic heterocyclyl, and a 5- to 6-membered monocyclic heteroaryl. The 4- to 7-membered monocyclic heterocyclyl and the 5- to 6-membered monocyclic heteroaryl are each independently selected from —OH, halogen, C 1~3 Alkoxy, and C 1~3 Optionally substituted with one group selected from alkyl.

[0208] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 8a are independently 4- to 7-membered monocyclic heterocyclyl or 5- to 6-membered monocyclic heteroaryl, and the 4- to 7-membered monocyclic heterocyclyl and the 5- to 6-membered monocyclic heteroaryl are each independently —OH, halogen, C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0209] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 8a are independently 4-membered monocyclic heterocyclyl or 5-membered monocyclic heteroaryl, each of which is selected from the group consisting of one C 1~3 Optionally substituted with alkyl.

[0210] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 8a is independently oxetanyl or a 5-membered monocyclic heteroaryl having two ring heteroatoms which are N, and the oxetanyl and the 5-membered monocyclic heteroaryl are each optionally substituted with methyl.

[0211] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 8a is independently oxetanyl or pyrazolyl, wherein oxetanyl and pyrazolyl are each optionally substituted with methyl.

[0212] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups may be -C(O)R 9 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8 is -C(O)R 9 is.

[0213] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 9 independently, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl or 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 Ra is optionally substituted with a group.

[0214] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 9 independently, C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl, 3~7 The monocyclic cycloalkyl and the 4- to 7-membered monocyclic heterocyclyl each independently have 1 to 4 R a is optionally substituted with a group.

[0215] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 9 independently, C 3~7 monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl, 3~7 monocyclic cycloalkyl and 4- to 7-membered monocyclic heterocyclyl, each independently selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 It is optionally substituted with 1 to 3 groups independently selected from alkyl and 4- to 7-membered monocyclic heterocyclyl.

[0216] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl includes -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkyl, and 4- to 7-membered monocyclic heterocyclyl. 9 One or both of 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl includes -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl, and 4- to 7-membered monocyclic heterocyclyl. 9 One or both of 3~7 It is a monocyclic cycloalkyl.

[0217] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of 7~10 It is a fused bicyclic cycloalkyl.

[0218] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of 5~10 Bridged bicyclic cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of 5~10 It is a bridged bicyclic cycloalkyl.

[0219] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is phenyl, and the phenyl is selected from 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is phenyl, and the phenyl is selected from 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of is phenyl.

[0220] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is naphthalenyl, and the naphthalenyl is selected from 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is naphthalenyl, and the naphthalenyl is selected from 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9One or both of is naphthalenyl.

[0221] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups is a 5- to 6-membered monocyclic heteroaryl.

[0222] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups is a fused 8- to 10-membered bicyclic heterocyclyl.

[0223] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups is a fused 8-10 membered bicyclic heteroaryl.

[0224] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups is a 7- to 10-membered spirocyclic heterocyclyl.

[0225] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups are 7-10 membered spirocyclic heterocyclyls, which have 1-2 ring heteroatoms independently selected from N and O.

[0226] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 teeth, [ka] is.

[0227] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyla In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, NR 11 R 11 , C 1~4 Alkoxy, C 1~5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkyl, and 4- to 7-membered monocyclic heterocyclyl. 9 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, NR 11 R 11 , C 1~4 Alkoxy, C 1~5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl, and 4- to 7-membered monocyclic heterocyclyl. 9 One or both of the groups is a 4- to 7-membered monocyclic heterocyclyl.

[0228] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 7-membered monocyclic heterocyclyl, and the 5- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl. 9 One or both of the groups is a 5- to 7-membered monocyclic heterocyclyl.

[0229] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 6-membered monocyclic heterocyclyl, and the 4- to 6-membered monocyclic heterocyclyl is a 4- to 6-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 6-membered monocyclic heterocyclyl, and the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 6-membered monocyclic heterocyclyl, and the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of —OH, halogen, C 1~3 Alkoxy and C 1~3In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 2 groups independently selected from alkyl. 9 is a 4- to 6-membered monocyclic heterocyclyl, and the 4- to 6-membered monocyclic heterocyclyl is a 4- to 6-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 6-membered monocyclic heterocyclyl, and the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl. 9 is a 4- to 6-membered monocyclic heterocyclyl, and the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of —OH, halogen, C 1~3 Alkoxy and C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 One or both of the groups are 4- to 6-membered monocyclic heterocyclyl.

[0230] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl. 9 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 3 groups independently selected from alkyl. 9 One or both of the groups is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0231] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of -OH, halogen, -CN, oxo, NR 11 R 11 , C 1~4 Alkoxy, C 1~5 It is optionally substituted with 1 to 3 groups independently selected from alkyl, and 4- to 7-membered monocyclic heterocyclyl.

[0232] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 4- to 7-membered monocyclic heterocyclyl; 4-7 membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; A 4- to 7-membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0233] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is substituted with —OH, halogen, C 1~3 Alkoxy and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkyl, and 5-6 membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0234] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is pyrrolidinyl or morpholinyl, each of which is selected from the group consisting of —OH, halogen, C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0235] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9is azetidinyl or pyrrolidinyl, each of which is selected from the group consisting of —OH, halogen, C 1~3 Alkoxy, and C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 2 groups independently selected from alkyl. 9 is azetidinyl or pyrrolidinyl, each of which is selected from the group consisting of —OH, halogen, C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 2 groups independently selected from alkyl.

[0236] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 teeth, [ka] Each of these is optionally substituted with 1 to 2 groups independently selected from -OH, methyl, and trifluoromethyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 9 teeth, [ka] Each of these is substituted with 1 to 2 groups independently selected from -OH, methyl and trifluoromethyl.

[0237] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 1~5 C optionally substituted with 1 to 3 groups independently selected from alkyl and 4- to 7-membered monocyclic heterocyclyl 3~7 It is a monocyclic cycloalkyl.

[0238] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9is cyclopropyl, cyclobutyl, or cyclopentanyl, each of which is selected from the group consisting of —OH, halogen, C 1~3 Alkoxy, C 1~3 It is optionally substituted with 1 to 2 groups independently selected from alkyl and 4- to 7-membered monocyclic heterocyclyl.

[0239] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is cyclopropyl, cyclobutyl, or cyclopentanyl, each of which is selected from the group consisting of —OH, halogen, C 1~3 Alkoxy, C 1~3 It is optionally substituted with 1 to 2 groups independently selected from alkyl and 5- to 7-membered monocyclic heterocyclyl, which has 1 or 2 ring heteroatoms that are N.

[0240] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is cyclopropyl optionally substituted with a 6-membered monocyclic heterocyclyl, which has one ring heteroatom which is N.

[0241] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 9 is cyclopropyl optionally substituted with morpholinyl.

[0242] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups may be -NR 10 R 10 is.

[0243] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 8 One or both of the groups are S(O)R 5a is.

[0244] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 8is -S(O)2R 5a is.

[0245] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 5a is a 4- to 7-membered monocyclic heterocyclyl. 4-7 membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; A 4- to 7-membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0246] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 5a is a 5- to 6-membered monocyclic heterocyclyl. 5-6 membered heterocyclyl includes -OH, halogen, -CN and C 1~5 optionally substituted with 1 to 2 groups independently selected from alkyl; A 5- to 6-membered heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0247] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 5a is piperazinyl.

[0248] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is —C(O)NR 6 R 7 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is —C(O)N(H)R 6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, Z is —C(O)N(CH)R 6 is.

[0249] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R6 is C 3~7 is a monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 7- to 10-membered spirocyclic heterocyclyl; C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 The bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0250] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl is one to three R b and optionally substituted with a group, A 4- to 7-membered monocyclic heterocyclyl is one to three R a is optionally substituted with a group.

[0251] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl; C 1~6 Alkyl is -OH, halogen, -NR 11 R 11 , and C 1~3 optionally substituted with 1 to 2 groups independently selected from alkoxy; 4-7 membered monocyclic heterocyclyl is -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0252] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~4 Alkoxy and C 1~5 Each alkyl is independently —OH, halogen, —CN, or —NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from:

[0253] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0254] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group having 1 to 4 R aIn some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is C 3~7 It is a monocyclic cycloalkyl.

[0255] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is C 7~10 It is a fused bicyclic cycloalkyl.

[0256] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R6 is C 5~10 It is a bridged bicyclic cycloalkyl.

[0257] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~4 Alkoxy and C 1~5 Each alkyl is independently —OH, halogen, —CN, or —NR 12 R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~3 Alkoxy and C 1~3 Each alkyl is independently —OH, halogen, —CN, or —NR 12 R 12In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 substituted with 1 to 3 groups independently selected from alkyl, C 1~3 Alkoxy and C 1~3 Alkyl is independently selected from -OH, halogen, -CN, and -NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from:

[0258] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy and C 1~5 substituted with 1 to 3 groups independently selected from alkyl, C 1~4 Alkoxy and C 1~5 Each alkyl is independently —OH, halogen, —CN, or —NR 12 R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3 substituted with 1 to 3 groups independently selected from alkyl, C 1~3 Alkoxy and C 1~3 Each alkyl is independently —OH, halogen, —CN, or —NR 12 R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, -NR 11 R 11 , C 1~3 Alkoxy and C 1~3 substituted with 1 to 3 groups independently selected from alkyl, C 1~3 Alkoxy and C 1~3 Each alkyl is independently —OH, halogen, —CN, or —NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from:

[0259] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 5- to 6-membered monocyclic heterocyclyl.

[0260] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 4- to 7-membered monocyclic heterocyclyl; 4-7 membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5and optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~4 Alkoxy and C 1~5 alkyl is, independently at each occurrence, —OH, halogen, —CN, and —NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from A 4- to 7-membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0261] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 5- to 6-membered monocyclic heterocyclyl; 5-6 membered heterocyclyl includes -OH, halogen, -CN and C 1~5 optionally substituted with 1 to 2 groups independently selected from alkyl; In the formula, C 1~5 The alkyl is optionally substituted with 1 to 2 groups independently selected from -OH and halogen.

[0262] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is pyrrolidinyl, piperidinyl or piperazinyl, each of which is selected from the group consisting of -OH, halogen, -CN and C 1~5 optionally substituted with 1 to 2 groups independently selected from alkyl, C 1~5 The alkyl is optionally substituted with 1 to 2 groups independently selected from -OH and halogen.

[0263] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is pyrrolidinyl, piperidinyl or piperazinyl, each of which is selected from the group consisting of one C 1~3 Optionally substituted with alkyl groups, C 1~3 The alkyl is optionally substituted with 1 to 2 groups independently selected from -OH and halogen.

[0264] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 teeth, [ka] Each of these is C 1~3 may be substituted with alkyl, C 1~3 The alkyl is substituted with one -OH group.

[0265] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is piperidinyl.

[0266] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0267] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0268] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is an 8- to 10-membered fused bicyclic heterocyclyl.

[0269] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0270] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0271] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0272] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 6 is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 6 is a 7- to 10-membered spirocyclic heterocyclyl.

[0273] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is H, C 1~6 Alkyl, C 3~7monocyclic cycloalkyl or 4- to 6-membered monocyclic heterocyclyl, 1~6 Alkyl, C 3~7 Monocyclic cycloalkyl and 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 7 is H or C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN and C 1~6 Optionally substituted with 1 to 4 groups independently selected from alkoxy.

[0274] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is H or C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is H or methyl.

[0275] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is H.

[0276] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, and C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 7 is C 1~6 alkyl, C 1~6 Alkyl is -OH, halogen, -CN, and C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 7 is C1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 7 is C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is methyl.

[0277] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyls include -OH, halogen, -CN, and C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 7 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyls include -OH, halogen, -CN, and C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 7 is C 3~7 It is a monocyclic cycloalkyl.

[0278] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is a 4- to 6-membered monocyclic heterocyclyl, and the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of —OH, halogen, —CN, and C 1~6 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 4 groups independently selected from alkoxy. 7 is a 4- to 6-membered monocyclic heterocyclyl, and the 4- to 6-membered monocyclic heterocyclyl is selected from the group consisting of —OH, halogen, —CN, and C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is substituted with 1 to 4 groups independently selected from alkoxy. 7is a 4-6 membered monocyclic heterocyclyl. In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 7 is oxetanyl.

[0279] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, Z is —C(O)R 13 is.

[0280] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, the 8- to 10-membered fused bicyclic heteroaryl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0281] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R a is optionally substituted with a group.

[0282] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and optionally substituted with 1 to 3 groups independently selected from:

[0283] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl are each independently —OH, halogen, —CN, oxo, —NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; C 1~5 Alkyl is -OH, halogen, -CN, and -NR 12 R 12 and optionally substituted with 1 to 2 groups independently selected from Each R 12 are independently H or C 1~3 It is alkyl.

[0284] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and each R 12 are independently H or C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0285] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and each R 12 are independently H or C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0286] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R is optionally substituted with 1 to 3 groups independently selected from alkyl. 13 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 and substituted with 1 to 3 groups independently selected from alkyl.

[0287] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl; 4-7 membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl; A 4- to 7-membered monocyclic heterocyclyl has 1 or 2 ring heteroatoms which are N.

[0288] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13is a 5- to 6-membered monocyclic heterocyclyl, and the 5- to 6-membered monocyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 Optionally substituted with 1 to 3 groups independently selected from alkyl.

[0289] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 5- to 6-membered monocyclic heterocyclyl.

[0290] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is piperazinyl.

[0291] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 5-6 membered monocyclic heteroaryl.

[0292] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and each R 12 are independently H or C 1~3 It is alkyl.

[0293] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and each R 12 are independently H or C 1~3 It is alkyl.

[0294] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is an 8- to 10-membered fused bicyclic heterocyclyl.

[0295] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and each R 12 are independently H or C 1~3 It is alkyl.

[0296] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R aIn some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is selected from -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and each R 12 are independently H or C 1~3 It is alkyl.

[0297] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0298] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 optionally substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and each R 12 are independently H or C 1~3 It is alkyl.

[0299] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 3 R a In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, R 13 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, and C 1~5 substituted with 1 to 3 groups independently selected from alkyl, C 1~5 Alkyl is -OH, halogen, -CN, oxo, and -NR 12 R 12 and each R 12 are independently H or C 1~3 It is alkyl.

[0300] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 13 is a 7- to 10-membered spirocyclic heterocyclyl.

[0301] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 5 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0302] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is H. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is C 1~6 alkyl, C 1~6 Alkyl is one to four R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is C 2~6 alkenyl, C2~6 Alkenyl is a group consisting of 1 to 4 R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is C 2~6 Alkynyl, C 2~6 Alkynyl is a group consisting of 1 to 4 R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is phenyl, and the phenyl is a group selected from 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is naphthalenyl, and naphthalenyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R aIn some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5 is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a is optionally substituted with a group.

[0303] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 10 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0304] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 10 are independently H or C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 10 are independently H or C 1~3 It is alkyl.

[0305] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 is H. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 One or both of 1~6 alkyl, C 1~6 Alkyl is one to four R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 One or both of1~3 alkyl, C 1~3 Alkyl is 1 to 4 R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 One or both of 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 One or both of 2~6 alkenyl, C 2~6 Alkenyl is a group consisting of 1 to 4 R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 One or both of 2~6 Alkynyl, C 2~6 Alkynyl is a group consisting of 1 to 4 R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 One or both of 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 One or both of 7~10 is a fused bicyclic cycloalkyl, C 7~10 Fused bicyclic cycloalkyl is 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 One or both of 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 is phenyl, and the phenyl is selected from 1 to 4 R aIn some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 is naphthalenyl, and the naphthalenyl is selected from 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 is a 6- to 10-membered bridged bicyclic heterocyclyl, and the 6- to 10-membered bridged bicyclic heterocyclyl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, R 10 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a is optionally substituted with a group.

[0306] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 5a independently, C1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 4 R b and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R a is optionally substituted with a group.

[0307] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is C 1~6 alkyl, C 1~6 Alkyl is one to four R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is C 2~6 alkenyl, C 2~6 Alkenyl is a group consisting of 1 to 4 R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is C 2~6Alkynyl, C 2~6 Alkynyl has 1 to 4 R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to four R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is phenyl, and the phenyl is a group selected from 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is naphthalenyl, and naphthalenyl is a group having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 4 R aIn some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is a fused bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 4 R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 5a is a 7- to 10-membered spirocyclic heterocyclyl, which is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 4 R a is optionally substituted with a group.

[0308] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R a are independently oxo, imino, halogen, -NO2, -N3, -CN, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11), -NR 11 R 11 , -N(R 11 )2(R 11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 1~6 Alkyl, C 2~6 Alkenyl, and C 2~6 Each alkynyl is independently 1 to 3 R c and optionally substituted with a group, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R d is optionally substituted with a group.

[0309] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R a are independently -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy or C 1~5 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R a are independently -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~3 Alkoxy, and C 1~3 It is alkyl.

[0310] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is imino. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a -OR 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -C(O)R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -C(O)OR 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R ais -C(O)N(R 11 )(R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -NR 11 R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -N(R 11 )2(R 11 ) + In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -N(R 11 )C(O)R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -N(R 11 )C(O)OR 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -N(R 11 )C(O)N(R 11 )(R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -N(R 11 )S(O)2(R 11a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -NR 11 S(O)2N(R 11 )(R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -NR 11 S(O)2O(R 11a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -OC(O)R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -OC(O)OR11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -OC(O)N(R 11 )(R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a -SR 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -S(O)R 11a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -S(O)(NH)R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -S(O)2R 11a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -S(O)2N(R 11 )(R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is -N=S(R 11a )(R 11a )=O.

[0311] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is C 1~6 alkyl, C 1~6 Alkyl has 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is C 2~6 alkenyl, C 2~6 Alkenyl has 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is C 2~6Alkynyl, C 2~6 Alkynyl has 1 to 3 R c is optionally substituted with a group.

[0312] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to three R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl has 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is phenyl, and the phenyl is a group selected from 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is naphthalenyl, and naphthalenyl is a group having 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 3 R dIn some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R a is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 3 R d is optionally substituted with a group.

[0313] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R b are independently oxo, imino, halogen, -NO2, -N3, -CN, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 11 , -C(O)R 11 , -C(O)OR 11 , -C(O)N(R 11 )(R 11 ), -NR 11 R 11 , -N(R 11 )2(R11 ) + , -N(R 11 )C(O)R 11 , -N(R 11 )C(O)OR 11 , -N(R 11 )C(O)N(R 11 )(R 11 ), -N(R 11 )S(O)2(R 11a ), -NR 11 S(O)2N(R 11 )(R 11 ), -NR 11 S(O)2O(R 11a ), -OC(O)R 11 , -OC(O)OR 11 , -OC(O)N(R 11 )(R 11 ), -SR 11 , -S(O)R 11a , -S(O)(NH)R 11 , -S(O)2R 11a , -S(O)2N(R 11 )(R 11 ), or -N=S(R 11a )(R 11a )=O, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R d is optionally substituted with a group.

[0314] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R b are independently -OH, halogen, -CN, oxo, -NR 11 R 11 , C 1~4 Alkoxy, C 3~7 Monocyclic cycloalkyl, C 7~10Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl.

[0315] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R b are independently -OH, halogen, -CN, oxo, -NR 11 R 11 , -C(O)N(R 11 )(R 11 ), C 1~4 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R b are independently -OH, halogen, -CN, oxo, -NR 11 R 11 , or C 1~4 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R is alkoxy. b are independently -OH, halogen, -CN, oxo, -NR 11 R 11 , or C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R b are independently halogen or C 1~3 It is an alkoxy.

[0316] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R b is independently a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, or a 6- to 10-membered bridged bicyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R bis a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is a 5- to 7-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is an 8- to 10-membered fused bicyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is a 6- to 10-membered bridged bicyclic heterocyclyl.

[0317] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is imino. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is halogen. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b -OR 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -C(O)R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -C(O)OR 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -C(O)N(R 11 )(R 11In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -NR 11 R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -N(R 11 )2(R 11 ) + In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -N(R 11 )C(O)R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -N(R 11 )C(O)OR 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -N(R 11 )C(O)N(R 11 )(R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -N(R 11 )S(O)2(R 11a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -NR 11 S(O)2N(R 11 )(R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -NR 11 S(O)2O(R 11a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -OC(O)R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -OC(O)OR 11In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -OC(O)N(R 11 )(R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b -SR 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -S(O)R 11a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -S(O)(NH)R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -S(O)2R 11a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -S(O)2N(R 11 )(R 11 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is -N=S(R 11a )(R 11a )=O.

[0318] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to three R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is C5~10 Bridged bicyclic cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl has 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is phenyl, and phenyl is a group consisting of 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is naphthalenyl, and naphthalenyl is a group having 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R b is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R bis a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 3 R d is optionally substituted with a group.

[0319] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R c are independently halogen, -CN, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a -S(O)(NH)R 12 , -S(O)2R 12a , -S(O)2N(R 12 )(R 12), or -N=S(R 12a )(R 12a )=O.

[0320] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is halogen. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is C 7~10 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is C 5~10 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is a 5-6 membered monocyclic heteroaryl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is an 8- to 10-membered fused bicyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is a 6- to 10-membered bridged bicyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is an 8-10 membered fused bicyclic heteroaryl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is a 7- to 10-membered spirocyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more Rc -OR 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -C(O)R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -C(O)OR 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -C(O)N(R 12 )(R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -NR 12 R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -N(R 12 )2(R 12 ) + In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -N(R 12 )C(O)R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -N(R 12 )C(O)OR 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -N(R 12 )C(O)N(R 12 )(R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is N(R 12 )S(O)2(R 12a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -NR 12 S(O)2N(R 12 )(R 12In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -NR 12 S(O)2O(R 12a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -OC(O)R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -OC(O)OR 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -OC(O)N(R 12 )(R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c -SR 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -S(O)R 12a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -S(O)(NH)R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -S(O)2R 12a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -S(O)2N(R 12 )(R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is -N=S(R 12a )(R 12a )=O.

[0321] In some embodiments of the compound of Formula I or II, or a pharmaceutically acceptable salt thereof, each R c are independently -OH, halogen, -CN, oxo, or -NR 12R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R c are independently -OH, halogen, -CN or -NR 12 R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R c is a halogen.

[0322] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R d are independently oxo, halogen, -CN, C 1~6 Alkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -NR 12 R 12 , -N(R 12 )2(R 12 ) + , -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12a ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12 S(O)2O(R 12a ), -OC(O)R12 , -OC(O)OR 12 , -OC(O)N(R 12 )(R 12 ), -SR 12 , -S(O)R 12a , -S(O)(NH)R 12 , -S(O)2R 12a , - S(O)2N(R 12 )(R 12 ), or -N=S(R 12a )(R 12a )=O, C 1~6 Alkyl is -OH, halogen, -CN, and C 1~3 Optionally substituted with 1 to 3 groups independently selected from alkoxy.

[0323] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is halogen. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is C 7~10 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is C 5~10 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R dis a 5-6 membered monocyclic heteroaryl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is an 8- to 10-membered fused bicyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is a 6- to 10-membered bridged bicyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is an 8-10 membered fused bicyclic heteroaryl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is a 7- to 10-membered spirocyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d -OR 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -C(O)R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -C(O)OR 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -C(O)N(R 12 )(R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -NR 12 R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -N(R 12 )2(R 12 ) + In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -N(R 12 )C(O)R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R dis -N(R 12 )C(O)OR 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -N(R 12 )C(O)N(R 12 )(R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -N(R 12 )S(O)2(R 12a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -NR 12 S(O)2N(R 12 )(R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -NR 12 S(O)2O(R 12a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -OC(O)R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -OC(O)OR 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -OC(O)N(R 12 )(R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d -SR 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -S(O)R 12a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -S(O)(NH)R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more Rd is -S(O)2R 12a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -S(O)2N(R 12 )(R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d is -N=S(R 12a )(R 12a )=O.

[0324] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R d -OH, halogens, -CN and C 1~3 C optionally substituted with 1 to 3 groups independently selected from alkoxy 1~6 It is alkyl.

[0325] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 11 are independently H, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R c is optionally substituted with a group.

[0326] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 11 are independently H, C 1~6 Alkyl, C 3~7 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 11 are independently H or C 1~4 alkyl, C 1~4 Alkyl is -OH and -NR 12 R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 11 are independently H or C 1~4 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 11 are independently H or C 1~3 In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 11 is independently H or methyl.

[0327] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 11 are independently H or C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 11 are independently H or C 1~3 It is alkyl.

[0328] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, —NR11 R 11 and -C(O)NR 11 R 11 Each R 11 are independently H or C 1~3 It is alkyl.

[0329] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is C 1~6 alkyl, C 1~6 Alkyl is one to three R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is C 1~4 alkyl, C 1~4 Alkyl is one to three R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is methyl.

[0330] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is H. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is C 2~6 alkenyl, C 2~6 Alkenyl is a group consisting of 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is C 2~6 Alkynyl, C 2~6 Alkynyl is a group consisting of 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 3 R cIn some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to three R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is phenyl, and the phenyl is a group selected from 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is naphthalenyl, and naphthalenyl is a group having 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 3 R c is optionally substituted with a group.

[0331] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 11a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl or 7- to 10-membered spirocyclic heterocyclyl; C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 3 R c is optionally substituted with a group.

[0332] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is C 1~6 alkyl, C 1~6 Alkyl is one to three R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is C 2~6 alkenyl, C 2~6 Alkenyl has 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11 a is C 2~6 Alkynyl, C 2~6 Alkynyl is a group consisting of 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is C 3~7 is a monocyclic cycloalkyl, C 3~7 Monocyclic cycloalkyl has 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is C 7~10 is a fused bicyclic cycloalkyl, C 7~10 A fused bicyclic cycloalkyl is one to three R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is C 5~10 Bridged bicyclic cycloalkyl, C 5~10 A bridged bicyclic cycloalkyl has 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is phenyl, and the phenyl is a group selected from 1 to 3 R cIn some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is naphthalenyl, and naphthalenyl is a group having 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is a 4- to 7-membered monocyclic heterocyclyl, and the 4- to 7-membered monocyclic heterocyclyl is a 4- to 7-membered monocyclic heterocyclyl having 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is a 5- to 6-membered monocyclic heteroaryl, and the 5- to 6-membered monocyclic heteroaryl is a 5- to 6-membered monocyclic heteroaryl having 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is an 8- to 10-membered fused bicyclic heterocyclyl, and the 8- to 10-membered fused bicyclic heterocyclyl is c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is a 6- to 10-membered bridged bicyclic heterocyclyl, which is a 6- to 10-membered bridged bicyclic heterocyclyl having 1 to 3 R c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is an 8- to 10-membered fused bicyclic heteroaryl, and the 8- to 10-membered fused bicyclic heteroaryl is c In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 11a is a 7- to 10-membered spirocyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl is a 7- to 10-membered spirocyclic heterocyclyl having 1 to 3 R c is optionally substituted with a group.

[0333] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 12 are independently H, C 1~6Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10 bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl.

[0334] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 12 are independently H or C 1~4 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, each R 12 are independently H or C 1~3 It is alkyl.

[0335] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is H. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is C 1~4 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is C 1~3 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is C 2~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is C 2~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is C 3~7In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is C 7~10 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is C 5~10 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is a 5-6 membered monocyclic heteroaryl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is an 8- to 10-membered fused bicyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is a 6- to 10-membered bridged bicyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is an 8-10 membered fused bicyclic heteroaryl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12 is a 7- to 10-membered spirocyclic heterocyclyl.

[0336] In some embodiments of the compound of Formula I or a pharmaceutically acceptable salt thereof, each R 12a independently, C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 3~7 Monocyclic cycloalkyl, C 7~10 Fused Bicyclic Cycloalkyl, C 5~10bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, or 7- to 10-membered spirocyclic heterocyclyl.

[0337] In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is C 1~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is C 2~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is C 2~6 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is C 3~7 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is C 7~10 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is C 5~10 In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is a 4- to 7-membered monocyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is a 5-6 membered monocyclic heteroaryl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12ais an 8- to 10-membered fused bicyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is a 6- to 10-membered bridged bicyclic heterocyclyl. In some embodiments of a compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is an 8-10 membered fused bicyclic heteroaryl. In some embodiments of the compound of Formula I, or a pharmaceutically acceptable salt thereof, one or more R 12a is a 7- to 10-membered spirocyclic heterocyclyl.

[0338] In one embodiment, [ka] a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof, are provided herein.

[0339] In one embodiment, [ka] a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof, are provided herein.

[0340] In one embodiment, [ka] a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof, are provided herein.

[0341] In one embodiment, [ka] a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof, are provided herein.

[0342] In one embodiment, [ka] a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof, are provided herein.

[0343] In one embodiment, [ka] a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof, are provided herein.

[0344] In one embodiment, [ka] a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof, are provided herein.

[0345] In one embodiment, [ka] a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof, are provided herein.

[0346] In one embodiment, [ka] a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof, are provided herein.

[0347] In one embodiment, [ka] a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof, are provided herein.

[0348] In one embodiment, [ka] a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof, are provided herein.

[0349] In one embodiment, [ka] a compound selected from the group consisting of or a pharmaceutically acceptable salt thereof, are provided herein. III. Compositions and Kits

[0350] The compounds provided herein, or their pharmaceutically acceptable salts, are usually administered in the form of pharmaceutical compositions.Therefore, pharmaceutical compositions comprising one or more of the compounds provided herein, or their pharmaceutically acceptable salts, isomers, or mixtures, and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants, and excipients are also provided herein.The compounds provided herein, or their pharmaceutically acceptable salts, may be the only active ingredient or one of the active ingredients of the pharmaceutical composition.Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents including sterile aqueous solutions and various organic solvents, penetration enhancers, solubilizers, and adjuvants.Such compositions are prepared in a manner well known in the pharmaceutical arts. See, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985), and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.).

[0351] In one embodiment, provided herein is a pharmaceutical composition comprising a compound provided herein (i.e., a compound of Formula I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

[0352] In some embodiments, the pharmaceutical compositions provided herein further comprise one or more (i.e., 1, 2, 3, 4; 1 or 2; 1 to 3; or 1 to 4) additional therapeutic agents, or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical compositions further comprise a therapeutically effective amount of one or more (i.e., 1, 2, 3, 4; 1 or 2; 1 to 3; or 1 to 4) additional therapeutic agents, or pharmaceutically acceptable salts thereof.

[0353] In some embodiments, the one or more additional therapeutic agents comprises an antimalarial agent, hi some embodiments, the antimalarial agent is selected from chloroquine and hydroxychloroquine, or a pharmaceutically acceptable salt thereof.

[0354] In some embodiments, the one or more additional therapeutic agents comprise an agent for the treatment of an inflammatory condition. In some embodiments, the one or more additional therapeutic agents comprise an agent for the treatment of an inflammatory condition. In some embodiments, the one or more additional therapeutic agents comprise an agent for the treatment of an inflammatory condition, such as veltuzumab, PF-06835375, eculizumab, milatuzumab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, celalizumab, daxudilimab, TAK-079, felzalutamab, itolizumab, anifrolumab, iscalimab, dapirolizumab pegol (dapirolizumab pegol, lanalumab, LY-3361237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obexelimab, talacuzumab, bovalilizumab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064, GNKS-356, AVO-101, rozibafusp α alfa), VRN-02, anexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, atacicept, telitacicept, BMS-986256, M-5049, KZR-616, KPG-818, verdinexor, ALPN-303, bulzifurocept, LA-1, cenerimod, prednisone, corticotropin, ducravacitinib, CPL-40911 6, CS-12192, tofacitinib citrate, ISB-830, DV-1079, duremic acid, iveldomid, TAM-01, BML-258, brepocitinib, SDC-1801, SDC-1802, ICP-330, NTR-441, darazatide, GSK-2646264, SKI-O-703, lanlaprenib (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 biosimilar, interleukin-2Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-x (SLE), AC-0058, fenebrutinib, XNW-1011, tirabrutinib hydrochloride, branebrutinib, ersbrutinib, orelabrutinib, DWP-213388, INV-103, R-salbutamol sulfate, anchorins, NIK-SMI1, X-6, INV-17, Oshadi D, baricitinib, upadacitinib, filgotinib, itacitinib, INCB-54707, delgocitinib, DWP-212525, CKD-971, azumometasone, betamethasone, foligerimod, anandamide, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (edoratide), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (h UC-MSC), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, and AMG-592, or a pharmaceutically acceptable salt of any of the foregoing, or any combination thereof.

[0355] The pharmaceutical compositions may be administered in either a single dose or multiple doses. The pharmaceutical compositions may be administered by a variety of methods, including, for example, rectal, oral, intranasal, and transdermal routes. In some embodiments, the pharmaceutical compositions may be administered by intraarterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, o...

Claims

1. A compound of formula I, 【Chemistry 102】 or a pharma- ceutically acceptable salt thereof, [In the formula, R １ is an 8- to 15-membered fused tricyclic heterocyclyl or an 8- to 15-membered fused tricyclic heteroaryl, said 8- to 15-membered fused tricyclic heterocyclyl and said 8- to 15-membered fused tricyclic heteroaryl each independently being selected from 1 to 4 R ａ is optionally substituted with a group; R ２ But, C １～６ alkyl, １～６ The alkyl is selected from halogen and C １～６ optionally substituted with 1 to 4 groups independently selected from alkoxy; Said C １～６ the alkoxy is optionally substituted with 1 to 3 halogen groups; R ３ H, halogen, -CN, C １～６ Alkyl and C ３～７ is a monocyclic cycloalkyl; Said C １～６ Alkyl and the C ３～７ Monocyclic cycloalkyls are each independently selected from -OH, halogen, -CN, and C １～４ optionally substituted with 1 to 3 groups independently selected from alkoxy; Said C １～４ the alkoxy is optionally substituted with 1 to 3 halogen groups; Z is C １～６ Alkyl, -C(O)R １３ -C(O)NR ６ R ７ , C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, a phenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl is 1 to 4 R ｂ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, ７～１０ Fused bicyclic cycloalkyl, ５～１０ The bridged bicyclic cycloalkyl, the 4- to 7-membered monocyclic heterocyclyl, the phenyl, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, the 8- to 10-membered fused bicyclic heteroaryl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R ８ groups, each independently being 1 to 3 R ａ is optionally substituted with a group; R ６ But, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, a 4- to 7-membered monocyclic heterocyclyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; R １３ is a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, the 8- to 10-membered fused bicyclic heteroaryl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R ａ is optionally substituted with a group; R ７ But, H, C １～６ Alkyl, C ３～７ monocyclic cycloalkyl, or 4- to 6-membered monocyclic heterocyclyl, １～６ Alkyl, C ３～７ The monocyclic cycloalkyl and the 4- to 6-membered monocyclic heterocyclyl are each independently selected from -OH, halogen, -CN, and C １～６ optionally substituted with 1 to 4 groups independently selected from alkoxy; Each R ８ are independently halogen, —C(O)R ９ , -NR １０ R １０ , C １～６ Alkyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, 4- to 7-membered monocyclic heterocyclyl, phenyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR ５ , -C(O)N(R ５ ) (R ５ ), -N(R ５ ) ２ (R ５ ) ＋ , -N(R ５ ) C(O)R ５ , -N(R ５ ) C(O)OR ５ , -N(R ５ ) C(O)N(R ５ ) (R ５ ), -N(R ５ ) S (O) ２ (R ５ａ ), -NR ５ S (O) ２ N (R ５ ) (R ５ ), -NR ５ S (O) ２ O (R ５ａ ), -OC(O)N(R ５ ) (R ５ ), -S(O)R ５ａ , -S(O)(NH)R ５ , -S(O) ２ R ５ａ , -S(O) ２ N (R ５ ) (R ５ ), or -N=S(R ５ａ ) (R ５ａ )=O, Said C １～６ Alkyl is 1 to 4 R ｂ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, ７～１０ Fused bicyclic cycloalkyl, ５～１０ The bridged bicyclic cycloalkyl, the 4- to 7-membered monocyclic heterocyclyl, the phenyl, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, the 8- to 10-membered fused bicyclic heteroaryl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 4 R ａ is optionally substituted with a group; Each R ９ But independently, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; Each R ５ and R １０ However, independently, H, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl, C ２～６ Alkenyl, and C ２～６ Alkynyl is independently 1 to 4 R ｂ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; Each R ５ａ But independently, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl, C ２～６ Alkenyl, and C ２～６ Alkynyl is independently 1 to 4 R ｂ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 4 R ａ is optionally substituted with a group; Each R ａ are independently oxo, imino, halogen, -NO ２ , -N ３ , -C.N., C. １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １１ , -C(O)R １１ , -C(O)OR １１ , -C(O)N(R １１ ) (R １１ ), -NR １１ R １１ , -N(R １１ ) ２ (R １１ ) ＋ , -N(R １１ ) C(O)R １１ , -N(R １１ ) C(O)OR １１ , -N(R １１ ) C(O)N(R １１ ) (R １１ ), -N(R １１ ) S (O) ２ (R １１ａ ), -NR １１ S (O) ２ N (R １１ ) (R １１ ), -NR １１ S (O) ２ O (R １１ａ ), -OC(O)R １１ , -OC(O)OR １１ , -OC(O)N(R １１ ) (R １１ ), -SR １１ , -S(O)R １１ａ , -S(O)(NH)R １１ , -S(O) ２ R １１ａ , -S(O) ２ N (R １１ ) (R １１ ), or -N=S(R １１ａ ) (R １１ａ )=O, Said C １～６ Alkyl, C ２～６ Alkenyl, and C ２～６ Alkynyl is independently 1 to 3 R ｃ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｄ is optionally substituted with a group; Each R ｂ are independently oxo, imino, halogen, -NO ２ , -N ３ , -C.N., C. ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １１ , -C(O)R １１ , -C(O)OR １１ , -C(O)N(R １１ ) (R １１ ), -NR １１ R １１ , -N(R １１ ) ２ (R １１ ) ＋ , -N(R １１ ) C(O)R １１ , -N(R １１ ) C(O)OR １１ , -N(R １１ ) C(O)N(R １１ ) (R １１ ), -N(R １１ ) S (O) ２ (R １１ａ ), -NR １１ S (O) ２ N (R １１ ) (R １１ ), -NR １１ S (O) ２ O (R １１ａ ), -OC(O)R １１ , -OC(O)OR １１ , -OC(O)N(R １１ ) (R １１ ), -SR １１ , -S(O)R １１ａ , -S(O)(NH)R １１ , -S(O) ２ R １１ａ , -S(O) ２ N (R １１ ) (R １１ ), or -N=S(R １１ａ ) (R １１ａ )=O, Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｄ is optionally substituted with a group; Each R ｃ are independently halogen, -CN, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １２ , -C(O)R １２ , -C(O)OR １２ , -C(O)N(R １２ ) (R １２ ), -NR １２ R １２ , -N(R １２ ) ２ (R １２ ) ＋ , -N(R １２ ) C(O)R １２ , -N(R １２ ) C(O)OR １２ , -N(R １２ ) C(O)N(R １２ ) (R １２ ), -N(R １２ ) S (O) ２ (R １２ａ ), -NR １２ S (O) ２ N (R １２ ) (R １２ ), -NR １２ S (O) ２ O (R １２ａ ), -OC(O)R １２ , -OC(O)OR １２ , -OC(O)N(R １２ ) (R １２ ), -SR １２ , -S(O)R １２ａ , -S(O)(NH)R １２ , -S(O) ２ R １２ａ , -S(O) ２ N (R １２ ) (R １２ ), or -N=S(R １２ａ ) (R １２ａ )=O, Each R ｄ are independently oxo, halogen, -CN, C １－６ Alkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １２ , -C(O)R １２ , -C(O)OR １２ , -C(O)N(R １２ ) (R １２ ), -NR １２ R １２ , -N(R １２ ) ２ (R １２ ) ＋ , -N(R １２ ) C(O)R １２ , -N(R １２ ) C(O)OR １２ , -N(R １２ ) C(O)N(R １２ ) (R １２ ), -N(R １２ ) S (O) ２ (R １２ａ ), -NR １２ S (O) ２ N (R １２ ) (R １２ ), -NR １２ S (O) ２ O (R １２ａ ), -OC(O)R １２ , -OC(O)OR １２ , -OC(O)N(R １２ ) (R １２ ), -SR １２ , -S(O)R １２ａ , -S(O)(NH)R １２ , -S(O) ２ R １２ａ , － S (O) ２ N (R １２ ) (R １２ ), or -N=S(R １２ａ ) (R １２ａ )=O, Said C １～６ Alkyl is -OH, halogen, -CN, and C １～３ optionally substituted with 1 to 3 groups independently selected from alkoxy; Each R １１ However, independently, H, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｃ is optionally substituted with a group; Each R １１ａ But independently, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｃ is optionally substituted with a group; Each R １２ However, independently, H, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Each R １２ａ But independently, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S; wherein each 8- to 15-membered fused tricyclic heterocyclyl and 8- to 15-membered fused tricyclic heteroaryl independently has 1 to 7 ring heteroatoms independently selected from N, O, and S; or a pharma- ceutically acceptable salt thereof.

2. Z is C ７～１０ a fused bicyclic cycloalkyl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or an 8- to 10-membered fused bicyclic heteroaryl; C ７～１０ The fused bicyclic cycloalkyl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, and 8- to 10-membered fused bicyclic heteroaryl each independently represent 1 to 2 R ８ groups, each independently being 1 to 3 R ａ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, optionally substituted with a group.

3. [In the formula, R １ But 1 to 4 R ａ is an 8- to 15-membered fused tricyclic heterocyclyl optionally substituted by a group; R ２ But, C １～６ alkyl, １～６ The alkyl is selected from halogen and C １～６ optionally substituted with 1 to 4 groups independently selected from alkoxy; Said C １～６ the alkoxy is optionally substituted with 1 to 3 halogen groups; R ３ is H or C １～６ is alkyl, Said C １～６ Alkyl is -OH, halogen, -CN, and C １～４ optionally substituted with 1 to 3 groups independently selected from alkoxy; Said C １～４ the alkoxy is optionally substituted with 1 to 3 halogen groups; Z is a 4- to 7-membered monocyclic heterocyclyl, phenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the phenyl, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R ８ groups, each independently being 1 to 3 R ａ is optionally substituted with a group; Each R ８ are independently -C(O)R ９ , C １～６ Alkyl, 4- to 7-membered monocyclic heterocyclyl or -S(O) ２ R ５ａ and Said C １～６ Alkyl is 1 to 4 R ｂ is optionally substituted with a group; The 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of 1 to 4 R ａ is optionally substituted with a group; Each R ９ But independently, C ３～７ monocyclic cycloalkyl or 4- to 7-membered monocyclic heterocyclyl; Said C ３～７ The monocyclic cycloalkyl and the 4- to 7-membered monocyclic heterocyclyl each independently represent 1 to 4 R ａ is optionally substituted with a group; R ５ａ is 4- to 7-membered monocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl is selected from the group consisting of 1 to 4 R ａ is optionally substituted with a group; Each R ａ are independently oxo, imino, halogen, -NO ２ , -N ３ , -C.N., C. １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １１ , -C(O)R １１ , -C(O)OR １１ , -C(O)N(R １１ ) (R １１ ), -NR １１ R １１ , -N(R １１ ) ２ (R １１ ) ＋ , -N(R １１ ) C(O)R １１ , -N(R １１ ) C(O)OR １１ , -N(R １１ ) C(O)N(R １１ ) (R １１ ), -N(R １１ ) S (O) ２ (R １１ａ ), -NR １１ S (O) ２ N (R １１ ) (R １１ ), -NR １１ S (O) ２ O (R １１ａ ), -OC(O)R １１ , -OC(O)OR １１ , -OC(O)N(R １１ ) (R １１ ), -SR １１ , -S(O)R １１ａ , -S(O)(NH)R １１ , -S(O) ２ R １１ａ , -S(O) ２ N (R １１ ) (R １１ ), or -N=S(R １１ａ ) (R １１ａ )=O, Said C １～６ Alkyl, C ２～６ Alkenyl, and C ２～６ Alkynyl is independently 1 to 3 R ｃ is optionally substituted with a group; Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｄ is optionally substituted with a group; Each R ｂ are independently oxo, imino, halogen, -NO ２ , -N ３ , -C.N., C. ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 8- to 10-membered bridged bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １１ , -C(O)R １１ , -C(O)OR １１ , -C(O)N(R １１ ) (R １１ ), -NR １１ R １１ , -N(R １１ ) ２ (R １１ ) ＋ , -N(R １１ ) C(O)R １１ , -N(R １１ ) C(O)OR １１ , -N(R １１ ) C(O)N(R １１ ) (R １１ ), -N(R １１ ) S (O) ２ (R １１ａ ), -NR １１ S (O) ２ N (R １１ ) (R １１ ), -NR １１ S (O) ２ O (R １１ａ ), -OC(O)R １１ , -OC(O)OR １１ , -OC(O)N(R １１ ) (R １１ ), -SR １１ , -S(O)R １１ａ , -S(O)(NH)R １１ , -S(O) ２ R １１ａ , -S(O) ２ N (R １１ ) (R １１ ), or -N=S(R １１ａ ) (R １１ａ )=O, Said C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｄ is optionally substituted with a group; Each R ｃ are independently halogen, -CN, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １２ , -C(O)R １２ , -C(O)OR １２ , -C(O)N(R １２ ) (R １２ ), -NR １２ R １２ , -N(R １２ ) ２ (R １２ ) ＋ , -N(R １２ ) C(O)R １２ , -N(R １２ ) C(O)OR １２ , -N(R １２ ) C(O)N(R １２ ) (R １２ ), -N(R １２ ) S (O) ２ (R １２ａ ), -NR １２ S (O) ２ N (R １２ ) (R １２ ), -NR １２ S (O) ２ O (R １２ａ ), -OC(O)R １２ , -OC(O)OR １２ , -OC(O)N(R １２ ) (R １２ ), -SR １２ , -S(O)R １２ａ , -S(O)(NH)R １２ , -S(O) ２ R １２ａ , -S(O) ２ N (R １２ ) (R １２ ), or -N=S(R １２ａ ) (R １２ａ )=O, Each R ｄ are independently oxo, halogen, -CN, C １－６ Alkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ Bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, 7- to 10-membered spirocyclic heterocyclyl, -OR １２ , -C(O)R １２ , -C(O)OR １２ , -C(O)N(R １２ ) (R １２ ), -NR １２ R １２ , -N(R １２ ) ２ (R １２ ) ＋ , -N(R １２ ) C(O)R １２ , -N(R １２ ) C(O)OR １２ , -N(R １２ ) C(O)N(R １２ ) (R １２ ), -N(R １２ ) S (O) ２ (R １２ａ ), -NR １２ S (O) ２ N (R １２ ) (R １２ ), -NR １２ S (O) ２ O (R １２ａ ), -OC(O)R １２ , -OC(O)OR １２ , -OC(O)N(R １２ ) (R １２ ), -SR １２ , -S(O)R １２ａ , -S(O)(NH)R １２ , -S(O) ２ R １２ａ , － S (O) ２ N (R １２ ) (R １２ ), or -N=S(R １２ａ ) (R １２ａ )=O, Each R １１ However, independently, H, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｃ is optionally substituted with a group; Each R １１ａ But independently, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Said C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ bridged bicyclic cycloalkyl, phenyl, naphthalenyl, 4- to 7-membered monocyclic heterocyclyl, 5- to 6-membered monocyclic heteroaryl, 8- to 10-membered fused bicyclic heterocyclyl, 6- to 10-membered bridged bicyclic heterocyclyl, 8- to 10-membered fused bicyclic heteroaryl, and 7- to 10-membered spirocyclic heterocyclyl are each independently selected from 1 to 3 R ｃ is optionally substituted with a group; Each R １２ However, independently, H, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; Each R １２ａ But independently, C １～６ Alkyl, C ２～６ Alkenyl, C ２～６ Alkynyl, C ３～７ Monocyclic cycloalkyl, C ７～１０ Fused Bicyclic Cycloalkyl, C ５～１０ a bridged bicyclic cycloalkyl, phenyl, naphthalenyl, a 4- to 7-membered monocyclic heterocyclyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, an 8- to 10-membered fused bicyclic heteroaryl, or a 7- to 10-membered spirocyclic heterocyclyl; each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S; 2. The compound of claim 1, wherein each 8-15 membered fused tricyclic heterocyclyl and 8-15 membered fused tricyclic heteroaryl independently has 1 to 7 ring heteroatoms independently selected from N, O, and S, or a pharma- ceutically acceptable salt thereof.

4. [In the formula, R １ is -OH, halogen, -CN, oxo, -NR １１ R １１ , C １～４ Alkoxy, C １～６ Alkyl and C ３～７ 8-15 membered fused tricyclic heterocyclyl optionally substituted with 1 to 3 groups independently selected from monocyclic cycloalkyl; R ２ But, C １～６ alkyl, １～６ The alkyl is selected from halogen and C １～６ optionally substituted with 1 to 4 groups independently selected from alkoxy; R ３ But, C １～６ alkyl, C １～６ Alkyl is -OH, halogen, -CN and C １～４ optionally substituted with 1 to 3 groups independently selected from alkoxy; Z is a 4- to 7-membered monocyclic heterocyclyl, phenyl, a 5- to 6-membered monocyclic heteroaryl, an 8- to 10-membered fused bicyclic heterocyclyl, a 6- to 10-membered bridged bicyclic heterocyclyl, or a 7- to 10-membered spirocyclic heterocyclyl; The 4- to 7-membered monocyclic heterocyclyl, the phenyl, the 5- to 6-membered monocyclic heteroaryl, the 8- to 10-membered fused bicyclic heterocyclyl, the 6- to 10-membered bridged bicyclic heterocyclyl, and the 7- to 10-membered spirocyclic heterocyclyl each independently represent 1 to 2 R ８ groups, each independently being selected from the group consisting of -OH, halogen, -CN, oxo, -NR １１ R １１ , C １～４ Alkoxy, and C １～５ optionally substituted with 1 to 3 groups independently selected from alkyl; Each R ８ are independently -C(O)R ９ , C １～６ Alkyl, 4- to 7-membered monocyclic heterocyclyl or -S(O) ２ R ５ａ and C １～６ Alkyl is -OH, halogen, -CN, oxo, -NR １１ R １１ , -C(O)NR １１ R １１ , C １～４ Alkoxy, and R ８ａ and optionally substituted with 1 to 3 groups independently selected from The 4- to 7-membered monocyclic heterocyclyl is -OH, halogen, -CN, oxo, -NR １１ R １１ , C １～４ Alkoxy, and C １～５ optionally substituted with 1 to 3 groups independently selected from alkyl; Each R ８ａ are independently 4- to 7-membered monocyclic heterocyclyl or 5- to 6-membered monocyclic heteroaryl, and the 4- to 7-membered monocyclic heterocyclyl and the 5- to 6-membered monocyclic heteroaryl are each independently selected from -OH, halogen, C １～４ Alkoxy and C １～５ optionally substituted with 1 to 3 groups independently selected from alkyl; Each R ９ But independently, C ３～７ is a monocyclic cycloalkyl or a 4- to 7-membered monocyclic heterocyclyl, ３－７ The monocyclic cycloalkyl and the 4- to 7-membered monocyclic heterocyclyl are each independently -OH, halogen, -CN, oxo, -NR １１ R １１ , C １～４ Alkoxy, C １～５ optionally substituted with 1 to 3 groups independently selected from alkyl and 4- to 7-membered monocyclic heterocyclyl; R ５ａ is a 4- to 7-membered monocyclic heterocyclyl, said 4- to 7-membered monocyclic heterocyclyl being -OH, halogen, -CN, oxo, -NR １１ R １１ , C １～４ Alkoxy, and C １～５ optionally substituted with 1 to 3 groups independently selected from alkyl; Each R １１ are independently H or C １～６ is alkyl, Each R １２ are independently H or C １～４ is alkyl, each 4-membered monocyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 5- to 7-membered monocyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 6-membered bridged bicyclic heterocyclyl has one ring heteroatom independently selected from N, O, and S; each 7-membered bridged bicyclic heterocyclyl independently has 1 to 2 ring heteroatoms independently selected from N, O, and S; each 5-6 membered monocyclic heteroaryl, 8-10 membered fused bicyclic heterocyclyl, 8-10 membered bridged bicyclic heterocyclyl, 8-10 membered fused bicyclic heteroaryl, and 7-10 membered spirocyclic heterocyclyl independently has 1 to 4 ring heteroatoms independently selected from N, O, and S; 2. The compound of claim 1, wherein each 8-15 membered fused tricyclic heterocyclyl and 8-15 membered fused tricyclic heteroaryl independently has 1 to 7 ring heteroatoms independently selected from N, O, and S, or a pharma- ceutically acceptable salt thereof.

5. R １ but, 【Chemistry 126】 and Halogen, C １～３ Alkyl and C １～３ Optionally substituted with 1 to 3 groups independently selected from alkoxy, wherein １～３ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein the alkyl is optionally substituted with 1 to 3 halogen groups.

6. R ２ But, C １～６ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.

7. R ３ is -OH, halogen, -CN and C １～３ C optionally substituted with 1 to 3 groups independently selected from alkoxy １～４ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.

8. One R ８ Z substituted with a group is 【Chemistry 111】 and Each R ８ But independently, i) 【Chemistry 112】 each of which may be substituted with one methyl group; or ii) C １～６ alkyl, １～６ Alkyl is -OH, halogen, -CN, oxo, -NR １１ R １１ , -C(O)NR １１ R １１ , C １～４ Alkoxy, and R ８ａ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, optionally substituted with 1 to 3 groups independently selected from:

9. Z is -C(O)NR ６ R ７ or -C(O)R １３ 2. The compound of claim 1, wherein:

10. R １１ is H or C １～３ 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.

11. 【Catalogue 127】 【Chemistry 128】 【Chemistry 129】 【Chemistry 130】 A compound selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient or carrier.

13. 12. A composition comprising a compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, for inhibiting the activity of Toll-like receptors 7 and / or 8 in a subject in need thereof.

14. A composition comprising a compound according to any one of claims 1 to 11 or a pharma- ceutically acceptable salt thereof, for the treatment of a disease or disorder associated with elevated Toll-like receptor 7 and / or 8 activity in a subject in need thereof.

15. 12. A composition comprising a compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, for the treatment of an inflammatory condition in a subject in need thereof.

16. 16. The composition of claim 15, wherein the inflammatory condition is selected from inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, glomerulonephritis, mixed connective tissue disease (MCTD), dermatomyositis, polymyositis, systemic sclerosis, antineutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, autoimmune hemolytic anemia, macrophage activation syndrome-driven anemia of inflammation, IgA nephropathy, type I diabetes, nonalcoholic steatohepatitis, and Sjogren's syndrome.

17. 12. A composition comprising a compound according to any one of claims 1 to 11 or a pharma- ceutically acceptable salt thereof, for the treatment of systemic lupus erythematosus in a subject in need thereof.

18. 12. A composition comprising a compound according to any one of claims 1 to 11 or a pharma- ceutically acceptable salt thereof, for the treatment of cutaneous lupus erythematosus in a subject in need thereof.

19. 12. A composition comprising a compound according to any one of claims 1 to 11 or a pharma- ceutically acceptable salt thereof, for the treatment of lupus nephritis in a subject in need thereof.

20. 16. The composition of claim 15, wherein the composition is administered in combination with one or more additional therapeutic agents, or pharma- ceutically acceptable salts thereof.

21. The one or more additional therapeutic agents are selected from the group consisting of veltuzumab, PF-06835375, eculizumab, milatuzumab, SM-06, SM-03, BT-063, QX-006-N, BOS-161721, AK-101, TNX-1500, celalizumab, daxudilimab, TAK-079, felzalutamab, itolizumab, anifrolumab, iscalimab, dapirolizumab pegol, ranalumab, LY-336 1237, JNJ-55920839, UBP-1213, DS-7011, PFI-102, BIIB-059, obexelimab, talacuzumab, bovalilizumab, TE-2324, PRV-3279, chloroquine, hydroxychloroquine, hydroxychloroquine sulfate, COV-08-0064, GNKS-356, AVO-101, rozibafusp α alfa), VRN-02, anexuzlimab, ALPN-101, bendamustine hydrochloride, BMS-986256, NKTR-35, atacicept, telitacicept, BMS-986256, M-5049, KZR-616, KPG-818, verdinexor, ALPN-303, buldifurocept, LA-1, cenerimod, prednisone, corticotropin, deuclavacitinib, CPL-40911 6, CS-12192, tofacitinib citrate, ISB-830, DV-1079, duremic acid, iverdomid, TAM-01, BML-258, brepositinib, SDC-1801, SDC-1802, ICP-330, NTR-441, darazatide, GSK-2646264, SKI-O-703, ranlaprenib (GS-9876), GNS-1653, HMPL-523, RSLV-132, interleukin-2 biosimilar, interleukin-2 Anteluke, interking recombinant human interleukin-2, ILT-101, CUG-252, DZ-2002, PEGylated HLA-x (SLE), AC-0058, fenebrutinib, XNW-1011, tirabrutinib hydrochloride, branebrutinib, ersbrutinib, olebrutinib, DWP-213388, INV-103, R-salbutamol sulfate, anchorins, NIK -SMI1, X-6, INV-17, Oshadi D, baricitinib, upadacitinib, filgotinib, itacitinib, INCB-54707, delgocitinib, DWP-212525, CKD-971, azumometasone, betamethasone, foligerimod, anandamide, DCB-SLE1, arsenic trioxide, tairuimide, TV-4710 (edoratide), allogeneic human umbilical cord-derived mesenchymal stem cell therapy (hUC-MSC ), LC-200, BI-705564, SM-934, GX-101, TXR-712, TXR-711, CIT-013, MHV-370, Panzyga®, TPX-6001, TPX-7001, artenimol, and AMG-592, or a pharma- ceutically acceptable salt of any of the foregoing, or any combination thereof.

Images